<SEC-DOCUMENT>0001144204-17-060464.txt : 20171121
<SEC-HEADER>0001144204-17-060464.hdr.sgml : 20171121
<ACCEPTANCE-DATETIME>20171121172336
ACCESSION NUMBER:		0001144204-17-060464
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20171121
DATE AS OF CHANGE:		20171121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SHINECO, INC.
		CENTRAL INDEX KEY:			0001300734
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE PRODUCTION - CROPS [0100]
		IRS NUMBER:				522175898
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-221711
		FILM NUMBER:		171217793

	BUSINESS ADDRESS:	
		STREET 1:		ROOM 1001, BUILDING T5, DAZU SQUARE,
		STREET 2:		DAXING DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			10022
		BUSINESS PHONE:		(86) 10-87227366

	MAIL ADDRESS:	
		STREET 1:		ROOM 1001, BUILDING T5, DAZU SQUARE,
		STREET 2:		DAXING DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			10022

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUPCOR, INC.
		DATE OF NAME CHANGE:	20050328

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Supcor, Inc.
		DATE OF NAME CHANGE:	20041015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SupCor, Inc.
		DATE OF NAME CHANGE:	20040817
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tv479787_s3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>As filed with
the Securities and Exchange Commission on November 21, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>Registration No.
333-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND
EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C.
20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>UNDER</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>THE SECURITIES
ACT OF 1933</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>SHINECO,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact name of
registrant as specified in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 49%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>52-2175898
    </B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation or organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Room
    1001, Building T5, DaZu Square,</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Daxing District, Beijing</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>People&rsquo;s Republic of China</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
    Intercorp, Inc.</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>113 Barksdale Professional Center</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Newark, Delaware 19711</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(302) 266-9367</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address, including
    zip code, and telephone number,</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">including area code, of registrant&rsquo;s principal
    executive offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name, address including
    zip code, and telephone&nbsp;</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">number, including area code, of agent for service)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Copy to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ying Li, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Hunter Taubman
Fischer &amp; Li, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1450 Broadway,
Floor 26</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, NY 10018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Tel: (212) 530-2210</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Facsimile: (212)
202-6380</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximate date of commencement of proposed sale to the public:&nbsp;As
soon as practicable after the effective date of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box. </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer,&nbsp; smaller&nbsp; reporting&nbsp; company,&nbsp;
or an emerging&nbsp; growth company.&nbsp; See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging&nbsp; growth company&rdquo;&nbsp; in&nbsp; Rule&nbsp; 12b-2&nbsp;
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated
    filer&nbsp;&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 55%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD NOWRAP STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD NOWRAP STYLE="width: 15%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do
    not check if a smaller reporting company)</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT>&nbsp;&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT>&nbsp;&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company,&nbsp; indicate&nbsp;
by&nbsp; check mark if&nbsp; the registrant&nbsp; has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided&nbsp; pursuant&nbsp; to Section&nbsp; 7(a)(2)(B) of&nbsp; the Securities
Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CALCULATION OF
REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Title&nbsp;of&nbsp;each&nbsp;class&nbsp;of&nbsp;securities&nbsp;to&nbsp;be
    registered</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount&nbsp;to&nbsp;be</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>registered<SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proposed<BR> maximum<BR>
    offering<BR> price&nbsp;per<BR> share</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>maximum</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>aggregate</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>offering</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>price<SUP>(2)</SUP></B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount&nbsp;of</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>registration</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>fee<SUP>(3)</SUP></B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%">Common Stock, $0.001 par value</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Preferred Stock, $0.001 par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities&nbsp;<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants&nbsp;<SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights&nbsp;<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units&nbsp;<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,112.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With respect to
    the primary offering, such indeterminate number or amount of debt securities, common stock, preferred stock, warrants and
    units to purchase any combination of the foregoing securities, and rights, as may from time to time be issued at indeterminate
    prices, with an aggregate initial offering price not to exceed $25,000,000. Securities registered hereunder may be sold separately
    or together in any combination with other securities registered hereunder.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In no event will
    the aggregate offering price of all securities issued from time to time pursuant to this registration statement exceed $25,000,000.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Estimated solely for the purpose of calculating
    the registration fee for a primary offering pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &quot;Securities
    Act&quot;). Pursuant to Rule 457(o) under the Securities Act and General Instruction II.D. of Form S-3, the table does not
    specify by each class information as to the amount to be registered or proposed maximum offering price per unit. The total
    amount is being paid herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to footnote
    (1), there are also being registered hereunder an indeterminate principal amount or number of shares of debt securities, preferred
    stock or common stock that may be issued upon conversion of, or in exchange for, debt securities or preferred stock registered
    hereunder or upon exercise of warrants registered hereunder, as the case may be</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes warrants
    to purchase common stock and warrants to purchase preferred stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>The registrant
hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such
date as the Commission, acting pursuant to Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The information
in this prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with
Securities and Exchange Commission. We may not sell any of the securities until the registration statement is filed with the Securities
and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer
to buy these securities in any state where offers or sales are not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SUBJECT
TO COMPLETION, DATED November 21, 2017</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SHINECO, INC.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$25,000,000.00</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may from time to
time, in one or more offerings at prices and on terms that we will determine at the time of each offering, offer common stock,
preferred stock, warrants, or a combination of these securities, or units, for an aggregate offering price of up to $25 million.
This prospectus describes the general manner in which our securities may be offered using this prospectus. Each time we offer
and sell securities, we will provide you with a prospectus supplement that will contain specific information about the terms of
that offering. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should
carefully read this prospectus and the applicable prospectus supplement as well as the documents incorporated or deemed to be
incorporated by reference in this prospectus before you purchase any of the securities offered hereby. This prospectus may not
be used to offer and sell securities unless accompanied by a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is
listed on the NASDAQ Capital Market under the symbol &ldquo;TYHT.&rdquo;&nbsp;&nbsp;On November 20, 2017, the last reported sales
price of our common stock was $3.53.&nbsp;We will apply to list any shares of common stock sold by us under this prospectus and
any prospectus supplement on the NASDAQ Capital Market. The prospectus supplement will contain information, where applicable,
as to any other listing of the securities on the NASDAQ Capital Market or any other securities market or exchange covered by the
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of November 20,
2017, the aggregate&nbsp;market value&nbsp;of our outstanding common stock held by non-affiliates is $59,823,517,based on 21,034,072
shares of outstanding common stock, of which approximately 16,947,172 shares are held by non-affiliates, and a per share price
of $3.53 based on the closing sale price of our common stock on November 20, 2017.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the 12 calendar
month period ended November 21, 2017, no shares&nbsp;of the common stock of the Company have been offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to General
Instruction I.B.6 of Form S-3, in no event will we sell our common stock in a public primary offering with a value exceeding more
than one-third of our public float in any 12-month period so long as our public float remains below $75 million. We have not offered
any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date
of this prospectus.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in any
of our common stock involves risk.&nbsp;&nbsp;You should carefully consider the Risk Factors beginning on page 3</I>&nbsp;<I>of
this prospectus in addition to Risk Factors contained in the applicable prospectus supplement, before you make an investment in
the securities.</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus if truthful or complete.&nbsp;&nbsp;Any representation to the contrary is a criminal offense.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may offer the securities
directly or through agents or to or through underwriters or dealers. If any agents or underwriters are involved in the sale of
the securities their names, and any applicable purchase price, fee, commission or discount arrangement between or among them,
will be set forth, or will be calculable from the information set forth, in an accompanying prospectus supplement. We can sell
the securities through agents, underwriters or dealers only with delivery of a prospectus supplement describing the method and
terms of the offering of such securities.&nbsp;&nbsp;See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The date of this
prospectus is November 21, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Page</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FORWARD-LOOKING
    INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DETERMINAITON OF OFFERING PRICE</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_005">22</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_006">22</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELLING SECURITY HOLDERS</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_007">22</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES TO
    BE REGISTERED</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND ADDITIONAL
    INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION INCORPORATED BY
    REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35&nbsp;</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only
on the information contained or incorporated by reference in this prospectus and any prospectus supplement.&nbsp;We have not authorized
any dealer, salesman or any other person to provide you with additional or different information.&nbsp;This prospectus and any
prospectus supplement are not an offer to sell or the solicitation of an offer to buy any securities other than the securities
to which they relate and are not an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any
person to whom it is unlawful to make an offer or solicitation in that jurisdiction.&nbsp;&nbsp;You should not assume that the
information in this prospectus or any prospectus supplement or in any document incorporated by reference in this prospectus or
any prospectus supplement is accurate as of any date other than the date of the document containing the information.&nbsp;We will
disclose any material changes in our affairs in a post-effective amendment to the registration statement of which this prospectus
is a part, a prospectus supplement, or a future filing with the Securities and Exchange Commission incorporated by reference in
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information contained
in this registration statement on Form S-3 includes some statements that are not purely historical and that are &ldquo;forward-looking
statements.&rdquo; Such forward-looking statements include, but are not limited to, statements regarding our company and our management&rsquo;s
expectations, hopes, beliefs, intentions or strategies regarding the future, including our financial condition and results of
operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances,
including any underlying assumptions, are forward-looking statements. The words &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo;
&ldquo;might,&rdquo; &ldquo;plans,&rdquo; &ldquo;possible,&rdquo; &ldquo;potential,&rdquo; &ldquo;predicts,&rdquo; &ldquo;projects,&rdquo;
&ldquo;seeks,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions, or the negatives of
such terms, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking
statements contained herein are based on current expectations and beliefs concerning future developments and the potential effects
on us. Future developments actually affecting us may not be those anticipated. These forward-looking statements involve a number
of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance
to be materially different from those expressed or implied by these forward-looking statements. Examples are statements regarding
future developments with respect to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         ability to improve internal controls and procedures;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
                                         and fluctuations in foreign currency exchange rates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         on-going ability to obtain all mandatory and voluntary government and other industry
                                         certifications, approvals, and/or licenses to conduct our business;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                         of a liquid trading market for our securities; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         costs we may incur in the future from complying with current and future governmental
                                         regulations and the impact of any changes in the regulations on our operations.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not rely
upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking
statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements
are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we nor
any other person assume responsibility for the accuracy and completeness of the forward-looking statements. Except as required
by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report
to conform these statements to actual results or to changes in our expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify all of
our forward-looking statements by these cautionary statements. The Company assumes no obligation to revise or update any forward-looking
statements for any reason, except as required by law.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is
part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, using a &ldquo;shelf&rdquo;
registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus
in one of more offerings up to a total dollar amount of proceeds of $25,000,000. This prospectus describes the general manner
in which our securities may be offered by this prospectus. Each time we sell securities, we will provide a prospectus supplement
that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change
information contained in this prospectus or in documents incorporated by reference in this prospectus. The prospectus supplement
that contains specific information about the terms of the securities being offered may also include a discussion of certain U.S.
Federal income tax consequences and any risk factors or other special considerations applicable to those securities. To the extent
that any statement that we make in a prospectus supplement is inconsistent with statements made in this prospectus or in documents
incorporated by reference in this prospectus, you should rely on the information in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully
read both this prospectus and any prospectus supplement together with the additional information described under &ldquo;Where
You Can Find Additional Information&rdquo; before buying any securities in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; and the &ldquo;Company&rdquo; refer only to Shineco, Inc. (&ldquo;TYHT&rdquo;) and its subsidiaries,
unless the context suggests otherwise. Additionally, unless we indicate otherwise, references in this prospectus to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;China&rdquo;
    and the &ldquo;PRC&rdquo; are to the People&rsquo;s Republic of China, excluding, for the purposes of this prospectus only,
    Taiwan and the special administrative regions of Hong Kong and Macau;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;RMB&rdquo;
    and &ldquo;Renminbi&rdquo; are to the legal currency of China; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;$,&rdquo;
    &ldquo;US$&rdquo; and &ldquo;U.S. dollars&rdquo; are to the legal currency of the United States.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><B>The
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Delaware
holding company that uses our subsidiaries&rsquo; and variable interest entities&rsquo; vertically- and horizontally-integrated
production, distribution and sales channels to provide health and well-being focused plant-based products. Our products are only
sold domestically in China. We utilize modern engineering technologies and biotechnologies to produce, among other products, Chinese
herbal medicines, organic agricultural produce and specialized textiles. Our health and well-being focused plant-based products
business is divided into three major segments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. Processing and
distributing traditional Chinese herbal medicine products as well as other pharmaceutical products. This segment is conducted
through Ankang Longevity Group, which operates 66 cooperative retail pharmacies throughout Ankang, a city in southern Shaanxi
province, China, through which we sell directly to individual customers traditional Chinese medicinal products produced by us
as well as by third parties. Ankang Longevity Group also owns a factory specializing in decoction, which is the process by which
solid materials are heated or boiled in order to extract liquids, and distributes decoction products to wholesalers and pharmaceutical
companies around China. This segment accounted for approximately 39.4% of our revenues for the year ended June 30, 2017. This
segment accounted for approximately 41.8% of our revenues for the three months period ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. Processing and
distributing green and organic agricultural produce as well as growing and cultivating yew trees (<I>taxus media</I>). We currently
cultivate and sell yew mainly to large group and corporate customers, but do not currently process yew into Chinese or Western
medicines. This segment is conducted through the Company&rsquo;s variable interest entities: the Zhisheng Group, which comprises
the following Chinese companies participating in our yew tree business: Shineco Zhisheng (Beijing) Bio-Technology Co. (&ldquo;Zhisheng
Bio-Tech&rdquo;), Yantai Zhisheng International Freight Forwarding Co., Ltd (&ldquo;Zhisheng Freight&rdquo;), Yantai Zhisheng
International Trade Co., Ltd (&ldquo;Zhisheng Trade&rdquo;), Yantai Mouping District Zhisheng Agricultural Produce Cooperative
(&ldquo;Zhisheng Agricultural&rdquo;), and Qingdao Zhihesheng Agricultural Produce Services, Ltd (&ldquo;Qingdao Zhihesheng&rdquo;).
This segment accounted for approximately 49.8% of our revenues for the year ended June 30, 2017. This segment accounted for approximately
44.8% of our revenues for the three months period ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. Developing and
distributing specialized fabrics, textiles and other byproducts derived from an indigenous Chinese plant&nbsp;<I>Apocynum Venetum</I>,
grown in the Xinjiang region of China, and known in Chinese as &ldquo;Luobuma&rdquo; or &ldquo;bluish dogbane&rdquo;. Our Luobuma
products are specialized textile and health supplement products designed to incorporate traditional Eastern medicines with modern
scientific methods. These products are predicated on centuries-old traditions of Eastern herbal remedies derived from the Luobuma
raw material. This segment is channeled through the Company&rsquo;s directly-owned subsidiary, Beijing Tenet-Jove Technological
Development Co., Ltd. (&ldquo;Tenet-Jove&rdquo;). This segment accounted for approximately 10.8% of our revenues for the year
ended June 30, 2017. This segment accounted for approximately 13.4% of our revenues for the three months period ended September
30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We primarily market
our health and wellbeing-focused products in China. At present, we do not sell any of our products in the United States or Canada.
China&rsquo;s domestic pharmaceutical and healthcare products market is fast-growing but, in our opinion, underdeveloped. We believe
China&rsquo;s healthcare sector has the capacity to develop even further. From pharmaceuticals to medical products to general
consumer health, China remains among the world&rsquo;s most attractive markets, and by far the fastest-growing of all the large
emerging ones. Driving this growth is China&rsquo;s aging population, increased incidence of chronic diseases, and a material
increase in investment from both domestic and foreign corporations. The growth also reflects the Chinese government&rsquo;s focus
on healthcare as both a social priority (as witnessed in its late 2000s healthcare reforms) and a strategic priority (as witnessed
in the 12<SUP>th</SUP>&nbsp;five-year plan&rsquo;s stated focus on growing the biomedical industry in the future).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
offices are located at Room 1001, Building T5, DaZu Square, Daxing District, Beijing, People&rsquo;s Republic of China. Our telephone
number is: (+86) 10-87227366.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>You should carefully
consider the following material risk factors and other information in this report. If any of the following risks actually occur,
our business, financial condition, results of operations and prospects for growth could be seriously impacted. As a result, the
trading price, if any, of our Common Stock could decline and you could lose part or all of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our significant business lines have
a limited operating history, which makes it difficult to evaluate our future prospects and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our Luobuma
business segment has been operational for 18 years, our pharmaceutical sales and yew plant segments have a limited operating history
and began operations in 2005 and 2013, respectively. In addition, those newer business segments account for a large portion (approximately
89%) of our operating results at this time. Accordingly, our past operating results may not be an accurate indication of the lines
of business we are principally engaged in currently. Thus, you should consider our future prospects in light of the risks and
uncertainties experienced by early stage companies in evolving markets rather than typical companies of our age. Some of these
risks and uncertainties relate to our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract additional
    customers and increased spending per customer;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase awareness
    of our brand and develop customer loyalty;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">respond to competitive
    market conditions and compete with existing competitors with broad recognition;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">respond to changes
    in our regulatory environment;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage risks associated
    with intellectual property rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain effective
    control of our costs and expenses;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise sufficient
    capital to sustain and expand our business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract, retain
    and motivate qualified personnel; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upgrade our technology
    to support additional research and development of new products.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unsuccessful
in addressing any of these risks and uncertainties, our business may be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The expansion of our business within
our existing business segments could significantly strain our resources, management and operational infrastructure, which could
impair our ability to meet increased demand for our products and hurt our business results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To accommodate our
anticipated expansion within our existing business lines&mdash;our pharmaceutical wholesale sales and yew plant segments&mdash;that
have a relatively limited operating history, we will need to expend capital resources and dedicate personnel to implement and
upgrade our accounting, distribution networks and operational infrastructure. We may need to recruit more personnel to train and
manage our growing and diverse employee base. If we cannot successfully implement these measures efficiently and cost-effectively,
we will be unable to satisfy the demand for our products, which will&nbsp;impair our revenue growth and hurt our overall financial
performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any disruption in the supply chain
of raw materials and our products could adversely impact our ability to produce and deliver products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As to the products
we manufacture, we must manage our supply chain for raw materials and delivery of our products. Supply chain fragmentation and
local protectionism within China further complicates supply chain disruption risks. Local administrative bodies and physical infrastructure
built to protect local interests pose transportation challenges for raw material transportation as well as product delivery throughout
China. In addition, profitability and volume could be negatively impacted by limitations inherent within the supply chain, including
competitive, governmental, legal, natural disasters, and other events that could impact both supply and price. Any of these occurrences
could cause significant disruptions to our supply chain, manufacturing capability and distribution system that could adversely
impact our ability to produce and deliver some of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The loss of any of our key customers
could reduce our revenues and our profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended
June 30, 2017, sales to our seven largest customers amounted in the aggregate to approximately 64% of our total revenue. For the
year ended June 30, 2016, sales to our five largest customers amounted in the aggregate to approximately 68% of our total revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three months
ended September 30, 2017, sales to our eight largest customers amounted in the aggregate to approximately 78% of our total revenue.
For the three months ended September 30, 2016, sales to our six largest customers amounted in the aggregate to approximately 82%
of our total revenue&nbsp;.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;There
can be no assurance that we will maintain or improve the relationships with these customers, or that we will be able to continue
to supply these customers at current levels or at all. Any loss of these customers could have a material negative effect on our
company&rsquo;s business. In addition, having a relatively small number of customers may cause our quarterly results to be inconsistent,
depending upon when these customers order and pay for outstanding invoices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, customers
in our yew plant segment tend to have long purchase cycles that average over two to three years. Thus, our major customers in
our yew plant segment for any given year do not tend to purchase products from us in the immediately following years. We must
maintain good business relationships with these customers in the years in which they are not purchasers of our yew plant products.
Additionally, we must procure orders from different customers each year in order to grow our sales. There is no assurance that
we will be able to accomplish this successfully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, consolidation
among our customers in recent years has resulted in additional customer concentration in the short term. If more of our existing
customers acquire one another or enter into joint venture relationships, we could experience additional concentration of our customer
base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three months
period ended September 30, 2017 and the years ended June 30, 2017 and 2016, we had eight, seven and five customers, respectively,
that each accounted for 5% or more of our revenues:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage of
    Revenues in</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Purchaser Name</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Three Months</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Period ended</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>September&nbsp;30,&nbsp;2017</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year ended</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>June&nbsp;30,&nbsp;2017</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year ended</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>June 30,&nbsp;2016</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 58%; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Qingdao City Association of
    Shipping Owners</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 11%; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 11%; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">8</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 11%; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">40</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Xi&rsquo;an Qianhe Pharmaceutical Co.,
    Ltd.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">8</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Shaanxi Pharmaceutical Group Pai&rsquo;ang
    Medicine Co. Ltd.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Ankang Beiyida Pharmaceutical Share Co.,
    Ltd.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Qingdao Shipping Services Association</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Qingdao Cruise and Yacht Association</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Qingdao ShiMeng Cruise Industrial Development
    Operation Management Co., Ltd.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Ziyan County Ziye Pharmaceutical Company</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Shaanxi Heyuan Commercial Co., Ltd. Medical
    Sub-branch</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;* </FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Shaanxi Fengdakailai Medical Co., Ltd.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Shaanxi Zhongcai &nbsp;Associated Medical
    Technology Co., Ltd.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Less
                                         than 5%</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot maintain
long-term relationships with these major customers, the loss of our sales to any of them could have an adverse effect on our business,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We buy our products from a relatively
limited number of vendors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We buy our products
from a limited number of vendors. For the three months period ended September 30, 2017, our nine largest vendors accounted for
approximately 92% &nbsp;of our total purchases. For the year ended June 30, 2017, our nine &nbsp;largest vendors accounted for
approximately 79% of our total purchases. During the year ended June 30, 2016, our nine largest vendors accounted for approximately
90% of our total purchases. During the three months period ended September 30, 2017 and the years ended June 30, 2017 and 2016,
we had nine, nine, and nine vendors, respectively, that each accounted for 5% or more of our purchases:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage of
    Purchases in</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Vendor Name</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Three Months</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Period Ended</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>September&nbsp;30,&nbsp;2017</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year ended</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>June 30,&nbsp;2017</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year ended</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>June&nbsp;30,&nbsp;2016</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 58%; text-align: justify"><FONT STYLE="font-size: 10pt">Qingdao Donglin Biological Engineering Co., Ltd.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">23</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">25</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Bozhou City Biaoma Pharmaceutal Trading Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sichuan Provincial Traditional Chinese Medicine Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Tianma (Anhui) Traditional Chinese Medicine Decoction Technology
    Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Tianma (Anhui) National Pharmaceutical Technology Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Anhui Bozhou City Wanzhen Traditional Chinese Medicine Co.,
    Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Anhui Bozhou Chinese Medicine Decoction Pieces Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Anhui Bozhou Guolong Pharmaceutical Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Qingdao Yinghuanhai International Logistics Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sichuan Zhongcheng Hengrui Pharmaceutical Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Dalian hanfang Biology Technology Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;* </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;* </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Baoji hanfang Chinese Medicine Decoction Pieces Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;* </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;* </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Anhui Bozhou Medicinal Materials Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;* </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;* </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Xunyang New Forest Ecological Agriculture Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;* </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;* </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Qingdao Longsheng Jieyun Express Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 5%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are a number
of suitable vendors who have the ability to supply raw materials to us, and we do not believe that our inability to use a particular
vendor would materially disrupt our business. However, because we currently purchase a material amount of our products from a
smaller number of suppliers, the loss of any such suppliers could result in increased expenses for our company and could result
in adverse impact on our business, financial condition and results of operations if we are unable to enter into an agreement with
a replacement supplier or suppliers on competitive terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our success depends on our ability
to protect our intellectual property. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We presently hold
one patent in the People&rsquo;s Republic of China for Luobuma fiber yarn preparation and an application method; we previously
obtained eight other patents, but as of the date of this filing, due to non-payment of the annual dues for such patents, they
are no longer valid. Our success depends on our ability to obtain and maintain patent protection for products developed from time
to time utilizing our technologies, in the PRC and in other countries, and to enforce these patents. There is no assurance that
any of our existing and future patents will be held valid and enforceable against third-party infringement or that our products
will not infringe any third-party patent or intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any patents relating
to our technologies may not be sufficiently broad to protect our products. In addition, our patents may be challenged, potentially
invalidated or potentially circumvented. Our patents may not afford us protection against competitors with similar technology
or permit the commercialization of our products without infringing third-party patents or other intellectual property rights.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on or
intend to rely on our trademarks, trade names and brand names to distinguish our products from the products of our competitors,
and have registered or will apply to register a number of these trademarks. However, third parties may oppose our trademark applications
or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced
to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising
and marketing these new brands. Further, our competitors may infringe our trademarks, or we may not have adequate resources to
enforce our trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our pharmaceutical business is subject
to inherent risks relating to product liability and personal injury claims.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmacies are exposed
to risks inherent in the manufacturing and distribution of pharmaceutical and other healthcare products, such as with respect
to improper filling of prescriptions, labeling of prescriptions, adequacy of warnings, and unintentional distribution of counterfeit
drugs. In addition, product liability claims may be asserted against us with respect to any of the products we sell and as a retailer,
we are required to pay for damages for any successful product liability claim against us, although with respect to products we
sell but do not manufacture, we may have the right under applicable PRC laws, rules and regulations to recover from the relevant
manufacturer for compensation we paid to our customers in connection with a product liability claim. We may also be obligated
to recall affected products. If we are found liable for product liability claims, we could be required to pay substantial monetary
damages. Furthermore, even if we successfully defend ourselves against this type of claim, we could be required to spend significant
management, financial and other resources, which could disrupt our business, and our reputation as well as our brand name may
also suffer. We, like many other similar companies in China, do not carry product liability insurance. As a result, any imposition
of product liability could materially harm our business, financial condition and results of operations. In addition, we do not
have any business interruption insurance due to the limited coverage of any available business interruption insurance in China,
and as a result, any business disruption or natural disaster could severely disrupt our business and operations and significantly
decrease our revenue and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The retail price of some of our
pharmaceutical products are subject to control by PRC authorities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A small number of
our pharmaceutical products (approximately 4% of our product offerings), primarily those included in the national and provincial
medical insurance catalogs, are subject to price controls in the form of fixed retail prices or retail price ceilings. Since May
1998, the relevant PRC governmental authorities have ordered price reductions on thousands of pharmaceutical products. Any future
price controls or government mandated price reductions may have a material adverse effect on our financial condition and results
of operations, including significantly reducing our revenue and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business requires a number of
permits and licenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drugstores in China
are required to obtain certain permits and licenses from various PRC governmental authorities, including Good Supply Practice
(&ldquo;GSP&rdquo;) certification. We are also required to obtain food hygiene certificates for the distribution of nutritional
supplements and food products other than medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, we participate
in the manufacture of Chinese medicine, which is subject to various PRC laws and regulations pertaining to the pharmaceutical
industry. We have obtained certificates, permits, and licenses required for the operation of a pharmaceutical enterprise and the
manufacturing of pharmaceutical products in the PRC. We are required to meet GSP standards in order to continue manufacturing
pharmaceutical products. We are required to renew the GSP every five years and our GSP for Ankang Longevity Chain was renewed
in August 2013. There is no guarantee we will be able to renew the GSP when it next expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you
that we can maintain all required licenses, permits and certifications to carry on our business at all times, and in the past
from time to time we may have not been in compliance with all such required licenses, permits and certifications. Moreover, these
licenses, permits and certifications are subject to periodic renewal and/or reassessment by the relevant PRC governmental authorities
and the standards of such renewal or reassessment may change from time to time. We intend to apply for the renewal of these licenses,
permits and certifications when required by then applicable laws and regulations. Any inability to renew these licenses, permits
and certifications could severely disrupt our business and prevent us from continuing to carry on our business. Any changes in
the standards used by governmental authorities in considering whether to renew or reassess our business licenses, permits and
certifications, as well as any enactment of new regulations that may restrict the conduct of our business, may also decrease our
revenue and/or increase our costs and materially reduce our profitability and prospects. Furthermore, if the interpretation or
implementation of existing laws and regulations changes or if new regulations come into effect requiring us to obtain any additional
licenses, permits or certifications that were previously not required to operate our existing businesses, we cannot assure you
that we may successfully obtain such licenses, permits or certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Corporate Structure
and Operation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on contractual arrangements
with our variable interest entities in China for our business operations, which may not be as effective in providing operational
control or enabling us to derive economic benefits as through ownership of controlling equity interests.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on and expect
to continue to rely on our wholly owned PRC subsidiary&rsquo;s contractual arrangements with our variable interest entities in
China and their respective shareholders. These contractual arrangements are not as effective in providing us with control over
the variable interest entities as ownership of controlling equity interests would be in providing us with control over, or enabling
us to derive economic benefits from the operations of, the affiliated consolidated entities. Under the current contractual arrangements,
as a legal matter, if any of the affiliated consolidated entities or any of their shareholders fails to perform its, his or her
respective obligations under these contractual arrangements, we may have to incur substantial costs and resources to enforce such
arrangements, and rely on legal remedies available under PRC laws, including seeking specific performance or injunctive relief,
and claiming damages, which we cannot assure you will be effective. For example, if shareholders of a variable interest entity
were to refuse to transfer their equity interests in such variable interest entity to us or our designated persons when we exercise
the purchase option pursuant to these contractual arrangements, we may have to take a legal action to compel them to fulfill their
contractual obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If (i) the applicable
PRC authorities invalidate these contractual arrangements for violation of PRC laws, rules and regulations, (ii) any variable
interest entity or its shareholders terminate the contractual arrangements or (iii) any variable interest entity or its shareholders
fail to perform their obligations under these contractual arrangements, our business operations in China would be materially and
adversely affected, and the value of your stock would substantially decrease. Further, if we fail to renew these contractual arrangements
upon their expiration, we would not be able to continue our business operations unless the then current PRC law allows us to directly
operate businesses in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if any
variable interest entity or all or part of its assets become subject to liens or rights of third-party creditors, we may be unable
to continue some or all of our business activities, which could materially and adversely affect our business, financial condition
and results of operations. If any of the variable interest entities undergoes a voluntary or involuntary liquidation proceeding,
its shareholders or unrelated third-party creditors may claim rights to some or all of these assets, thereby hindering our ability
to operate our business, which could materially and adversely affect our business and our ability to generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of these contractual
arrangements are governed by PRC law and provide for the resolution of disputes through arbitration in the PRC. The legal environment
in the PRC is not as developed as in some other jurisdictions, such as the United States. As a result, uncertainties in the PRC
legal system could limit our ability to enforce these contractual arrangements. Moreover, if a court were to determine that these
contracts are not in the public interest or otherwise contrary to government policy, it could choose not to enforce such contracts,
even if the contractual obligations were otherwise clear. In the event we are unable to enforce these contractual arrangements,
we may not be able to exert effective control over our operating entities and we may be precluded from operating our business,
which would have a material adverse effect on our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Proposed legislation in the PRC</I>&nbsp;<I>could
adversely affect our corporate structure, corporate governance and business operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2015, China&rsquo;s
Ministry of Commerce, or MOFCOM, released a discussion draft of the proposed Foreign Investment Law (&ldquo;Discussion Draft&rdquo;),
soliciting comments from the public. The Discussion Draft is aimed to replace, upon its enactment, existing laws regulating foreign
investments in China with a uniform law and, if adopted, could affect a wide range of foreign entities, including our Company,
and investments generally in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proposed legislation
is just a draft proposal at this time, and it is uncertain when, if ever, MOFCOM will submit the final version of the proposed
law to the PRC&rsquo;s National People&rsquo;s Congress for review and passage. The proposed legislation may never be submitted
for approval, or if submitted it may not be passed by the National People&rsquo;s Congress. Alternatively, the version submitted
(or approved) may be materially different than the current proposed draft. Thus, like any proposed legislation, the potential
impact of such legislation on foreign investments in China and the business operations of China-based companies is unknown. We
are currently working with our legal and accounting advisers to develop strategies to minimize the impact potential changes to
existing Chinese laws regulating foreign investments might have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Discussion
Draft as it is currently written, variable interest entities, or &ldquo;VIEs,&rdquo; that are controlled through their contractual
arrangements could be deemed a foreign-invested enterprise if they are deemed to be ultimately &ldquo;controlled&rdquo; by foreign
investors. Therefore, for a company such as us with a VIE structure in an industry designated as a &ldquo;restricted&rdquo; or
&ldquo;prohibited&rdquo; to foreign investment, the VIE structure may be deemed legitimate if the ultimate controlling persons
are PRC citizens or PRC entities. If the ultimate controlling persons are not PRC citizens or PRC entities, then the VIEs may
be treated as foreign-invested enterprises and operation in the restricted or prohibited industries may require market entry clearance,
national security review, and certain information reporting obligations. At this time we believe that under the current version
of the Discussion Draft, our VIE structure should be deemed legitimate, as the expected ultimate controlling persons will be PRC
citizens or PRC entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of
this registration statement, no formal legislation has been implemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>An insufficient amount of insurance
could expose us to significant costs and business disruption.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not purchased
any insurance to cover our assets and property, which could leave our business inadequately protected from loss. If we were to
incur substantial losses or liabilities due to fire, explosions, floods, other natural disasters or accidents or business interruption,
our results of operations could be materially and adversely affected.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an &ldquo;emerging growth
company,&rdquo; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make
our common stock less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. For as long as we continue to be
an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other
public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports
and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
shareholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to
five years, although we could lose that status sooner if our revenues exceed $1 billion, if we issue more than $1 billion in non-convertible
debt in a three year period, or if the market value of our common stock held by non-affiliates exceeds $700 million as of any
June 30 before that time, in which case we would no longer be an emerging growth company as of the following December 31. We cannot
predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find
our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price
may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the JOBS Act,
emerging growth companies can also delay adopting new or revised accounting standards. We have irrevocably elected not to avail
our company of these exemptions from new or revised accounting standards and, therefore, will be subject to the same new or revised
accounting standards as other public companies that are not emerging growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Offering and Our
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market price of our common stock
may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above
the offering price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offering price
for our common stock will be determined by our Company and may vary from the market price of our common stock following our offering.
If you purchase our common stock in our offering, you may not be able to resell those shares at or above the offering price. We
cannot assure you that the offering price of our common stock, or the market price following our offering, will equal or exceed
prices in privately negotiated transactions of our shares that have occurred from time to time prior to our offering. The market
price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated
    fluctuations in our revenue and other operating results;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the financial projections
    we may provide to the public, any changes in these projections or our failure to meet these projections;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions of securities
    analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our
    company, or our failure to meet these estimates or the expectations of investors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by
    us or our competitors of significant products or features, technical innovations, acquisitions, strategic partnerships, joint
    ventures, or capital commitments;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">price and volume
    fluctuations in the overall stock market, including as a result of trends in the economy as a whole;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lawsuits threatened
    or filed against us; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or
    factors, including those resulting from war or incidents of terrorism, or responses to these events.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the stock
markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of
equity securities of many companies. Stock prices of many companies have fluctuated in a manner unrelated or disproportionate
to the operating performance of those companies. In the past, stockholders have filed securities class action litigation following
periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs,
divert resources and the attention of management from our business, and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Provisions
in our By-laws and Delaware laws might discourage, delay or prevent a change of control of our company or changes in our management
and, therefore, depress the trading price of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our
by-laws and Delaware laws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders
may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our Common Stock.
These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                         on the removal of directors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                         on the ability of our shareholders to call special meetings;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                         advance notice provisions for shareholder proposals and nominations for elections to
                                         the board of directors to be acted upon at meetings of shareholders;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
                                         that the board of directors is expressly authorized to adopt, or to alter or repeal our
                                         bylaws; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                         advance notice and certain information requirements for nominations for election to our
                                         board of directors or for proposing matters that can be acted upon by shareholders at
                                         shareholder meetings.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are
subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging
in any of a broad range of business combinations with an interested stockholder for a period of three years following the date
on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. The
existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay
in the future for shares of our Common Stock. They could also deter potential acquirers of our company, thereby reducing the likelihood
that you could receive a premium for your Common Stock in an acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We may
issue preferred stock whose terms could adversely affect the voting power or value of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of
incorporation authorizes us to issue, without the approval of our shareholders, one or more classes or series of preferred stock
having such designations, preferences, limitations and relative rights, including preferences over our common stock respecting
dividends and distributions, as our board of directors may determine. The terms of one or more classes or series of preferred
stock could adversely impact the voting power or value of our common stock. For example, we might grant holders of preferred stock
the right to elect some number of our directors in all events or on the happening of specified events or the right to veto specified
transactions. Similarly, the repurchase or redemption rights or liquidation preferences we might assign to holders of preferred
stock could affect the residual value of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to maintain effective
internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our
financial reports and the market price of our common stock, may decline, and we may have difficulty raising additional capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company,
we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control.
In addition, we are required to furnish a report by management on the effectiveness of our internal control over financial reporting
pursuant to Section 404 of the Sarbanes-Oxley Act. We will continue to incur considerable costs and use significant management
time and other resources in an effort to comply with Section 404 and other requirements of the Sarbanes-Oxley Act.&nbsp; In addition,
our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over
financial reporting beginning with our annual report on Form 10-K following the date on which we are no longer an &ldquo;emerging
growth company,&rdquo; which may be up to five full years following the date of this offering. If we identify material weaknesses
in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 in a timely
manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting
firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting when required, investors
may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be
negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the
Securities and Exchange Commission, or other regulatory authorities, which could require additional financial and management resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The requirements of being a public
company may strain our resources and divert management&rsquo;s attention.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company,
we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley
Act, the Dodd-Frank Act, the listing requirements of the securities exchange on which we list, and other applicable securities
rules and regulations. Despite recent reforms made possible by the JOBS Act, compliance with these rules and regulations has high
legal, accounting, and financial compliance costs and&nbsp;investor relations and public relations costs, make some activities
more difficult, time-consuming or costly and increases demand on our systems and resources, particularly after we are no longer
an &ldquo;emerging growth company.&rdquo; The Exchange Act requires, among other things, that we file annual, quarterly, and current
reports with respect to our business and operating results as well as proxy statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of disclosure
of information in this prospectus and in filings required of a public company, our business and financial condition is more visible,
which we believe may result in threatened or actual litigation, including by competitors and other third parties. If such claims
are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are
resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management
and adversely affect our business, brand and reputation and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These rules and regulations
will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced
coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract
and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee,
and qualified executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have broad discretion in the
use of the net proceeds from our offering and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent (i)
we raise more money than required for the purposes explained in the section titled &ldquo;Use of Proceeds&rdquo; or (ii) we determine
that the proposed uses set forth in that section are no longer in the best interests of our Company, we cannot specify with any
certainty the particular uses of such net proceeds that we receive from the offering. Our management will have broad discretion
in the application of such net proceeds, including working capital, possible acquisitions, and other general corporate purposes,
and we may spend or invest these proceeds in a way with which our shareholders disagree. The failure by our management to apply
these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from
the offering in a manner that does not produce income or that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay dividends
for the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently intend
to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any
dividends in the foreseeable future. As a result, you may only receive a return on your investment in our common stock if the
market price of our common stock increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If a more active trading market
for our common stock develops, the market price of our common stock is likely to be highly volatile and subject to wide fluctuations,
and holders of our common stock may be unable to sell their shares at or above the price at which they were acquired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of
our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to a number of factors
that are beyond our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quarterly
    variations in our revenues and operating expenses;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    in the financial markets and worldwide economies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of
    innovations or new products or services by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by
    the PRC government relating to regulations that govern our industry;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant sales
    of our common stock or other securities in the open market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in interest
    rates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market
    valuations of other comparable companies; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in accounting
    principles.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The obligation to disclose information
publicly may put us at a disadvantage to competitors that are private companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company
in the United States, we are required to file periodic reports with the Securities and Exchange Commission upon the occurrence
of matters that are material to our company and shareholders. Although we may be able to attain confidential treatment of some
of our developments, in some cases, we will need to disclose material agreements or results of financial operations that we would
not be required to disclose if we were a private company. Our competitors will have access to this information, which would otherwise
be confidential. This may give them advantages in competing with our company. Similarly, as a U.S. public company, we will be
governed by U.S. laws that our competitors, which are mostly private Chinese companies, are not required to follow. To the extent
compliance with U.S. laws increases our expenses or decreases our competitiveness against such companies, our public company status
could affect our results of operations.&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate and
substantial dilution.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offering price
of our shares may be substantially higher than the pro forma net tangible book value per share of our common stock. Accordingly,
if you purchase shares in this offering, you may incur immediate and substantial dilution of your investment. See &ldquo;Dilution&rdquo;
on page 22.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A sale or perceived sale of a substantial
number of shares of our common stock may cause the price of our common stock to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our shareholders
sell substantial amounts of our common stock in the public market, the market price of our common stock could fall. Moreover,
the perceived risk of this potential dilution could cause shareholders to attempt to sell their shares and investors to short
our common stock. These sales also may make it more difficult for us to sell equity or equity-related securities in the future
at a time and price that we deem reasonable or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Doing Business in
China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PRC regulation of loans to, and
direct investments in, PRC entities by offshore holding companies may delay or prevent us from using proceeds from this offering
and/or future financing activities to make loans or additional capital contributions to our PRC operating subsidiaries.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an offshore holding
company with PRC subsidiaries, we may transfer funds to our PRC subsidiaries or finance our operating entity by means of loans
or capital contributions. Any loans to our PRC subsidiaries, which are foreign-invested enterprises, cannot exceed statutory limits
based on the difference between the amount of our investments and registered capital in such subsidiaries, and shall be registered
with China&rsquo;s State Administration of Foreign Exchange (&ldquo;SAFE&rdquo;), or its local counterparts. Furthermore, any
capital increase contributions we make to our PRC subsidiaries, which are foreign-invested enterprises, shall be approved by China&rsquo;s
Ministry of Commerce (&ldquo;MOFCOM&rdquo;), or its local counterparts. We may not be able to obtain these government registrations
or approvals on a timely basis, if at all. If we fail to receive such registrations or approvals, our ability to provide loans
or capital to increase contributions to our PRC subsidiaries may be negatively affected, which could adversely affect our liquidity
and our ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PRC state administration of foreign
exchange (&quot;SAFE&quot;) regulations regarding offshore financing activities by PRC residents which may increase the administrative
burden we face. The failure by our shareholders who are PRC residents to make any required applications and filings pursuant to
such regulations&nbsp;may prevent us from being able to distribute profits and could expose us and our PRC resident shareholders
to liability under PRC law.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SAFE, issued a public
notice (&quot;SAFE #75&quot;) effective from November 1, 2005, which requires registration with&nbsp;SAFE&nbsp;by the PRC resident
shareholders of any foreign holding company of a PRC entity. Without registration, the PRC entity cannot&nbsp;remit&nbsp;any of
its profits out of the PRC as dividends or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2005,&nbsp;SAFE&nbsp;issued
a public notice, the Notice on Relevant Issues in the Foreign Exchange Control over Financing and Return Investment Through Special
Purpose Companies by Residents Inside China, or the SAFE notice, which requires PRC residents, including both legal persons and
natural persons, to register with the competent local SAFE branch before establishing or controlling any company outside of China,
referred to as an &quot;offshore special purpose company,&quot; for the purpose of overseas equity financing involving onshore
assets or equity interests held by them. In addition, any PRC resident that is the shareholder of an offshore special purpose
company is required to amend its SAFE registration with the local SAFE branch with respect to that offshore special purpose company
in connection with any increase or decrease of capital, transfer of shares, merger, division, equity investment or creation of
any security interest over any assets located in China. Moreover, if the offshore special purpose company was established and
owned the onshore assets or equity interests before the implementation date of the SAFE notice, a retroactive SAFE registration
is required to have been completed before March 31, 2006. If any PRC shareholder of any offshore special purpose company fails
to make the required SAFE registration and amendment, the PRC subsidiaries of that offshore special purpose company may be prohibited
from distributing their profits and the proceeds from any reduction in capital, share transfer or liquidation to the offshore
special purpose company. Moreover, failure to comply with the SAFE registration and amendment requirements described above could
result in liability under PRC laws for evasion of applicable foreign exchange restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is unclear whether
our other PRC resident shareholders must make disclosure to SAFE. We believe that only PRC resident shareholders who receive ownership
of the foreign holding company in exchange for ownership in the PRC operating company are subject to SAFE #75, there can be no
assurance that SAFE will not require our other PRC resident shareholders to register and make the applicable disclosure. In addition,
SAFE #75 requires that any monies remitted to PRC residents outside of the PRC be returned within&nbsp;180 days; however, there
is no indication of what the penalty will be for failure to comply or if shareholder non-compliance will be considered to be a
violation of SAFE #75 by us or otherwise affect us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that
the proper procedures are not followed under&nbsp;SAFE&nbsp;#75, we could lose the ability to&nbsp;remit&nbsp;monies outside of
the PRC and would therefore be unable to pay dividends or make other distributions. Our PRC resident shareholders could be subject
to fines, other sanctions and even criminal liabilities under the PRC Foreign Exchange Administrative Regulations promulgated
January 29, 1996, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Labor disputes could significantly
affect our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Labor disputes with
our employees or labor disputes regarding social welfare could significantly disrupt operations or expansion plans. Delays caused
by any such disruptions could materially affect projections for increased capacity, production and revenues, which could have
a material adverse effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Labor laws in the PRC may adversely
affect our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Labor Contract
Law of the PRC imposes greater liabilities on employers and significantly affects the cost of an employer&rsquo;s decision to
reduce its workforce. Further, it requires certain terminations be based upon seniority and not merit. In the event we decide
to significantly change or decrease our workforce, the Labor Contract Law could adversely affect our ability to enact such changes
in a manner that is most advantageous to our business or in a timely and cost-effective manner, thus materially and adversely
affecting our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The cessation of tax exemptions
and deductions by the Chinese government may affect our profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our business
is agricultural, we benefit from value added tax (&ldquo;VAT&rdquo;) and income tax exemption status for Qingdao Zhihesheng and
Zhisheng Agricultural. Ankang Longevity Group also benefits from VAT exemptions from the purchase of raw materials used in Chinese
medicine. If China&rsquo;s law with respect to these tax exemptions changes, it will have significant effect on our net profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The rental of collective land requires
the permission of local residents or the local government.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our agricultural business
requires the rental of collective land which may be revoked by the committee of collective rural residents or the local government
if the use of the land does not comply with the original rental agreement and relevant regulations to use the land for agriculture
purposes. While we will continue to strive for compliance with the rental agreement and relevant regulations, should such revoking
situation occur, we would further negotiate with the relevant local government to revise the agreement for the continued use of
the land.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Adverse changes in political and
economic policies of the PRC government could have a material adverse effect on the overall economic growth of China, which could
reduce the demand for our products and materially and adversely affect our competitive position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantially all
of our business operations are conducted in China. Accordingly, our business, results of operations, financial condition and prospects
are subject to economic, political and legal developments in China. Although the Chinese economy is no longer a planned economy,
the PRC government continues to exercise significant control over China&rsquo;s economic growth through direct allocation of resources,
monetary and tax policies, and a host of other government policies such as those that encourage or restrict investment in certain
industries by foreign investors, control the exchange between RMB and foreign currencies, and regulate the growth of the general
or specific market. These government involvements have been instrumental in China&rsquo;s significant growth in the past 30 years.
In response to the recent global and Chinese economic slowdown, the PRC government has adopted policy measures aimed at stimulating
the economic growth in China. If the PRC government&rsquo;s current or future policies fail to help the Chinese economy achieve
further growth or if any aspect of the PRC government&rsquo;s policies limits the growth of our industry or otherwise negatively
affects our business, our growth rate or strategy, our results of operations could be adversely affected as a result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Under the Enterprise Income Tax
Law, we may be classified as a &ldquo;Resident Enterprise&rdquo; of China. Such classification will likely result in unfavorable
tax consequences to us and our non-PRC shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China passed the Enterprise
Income Tax Law, or the EIT Law, and it is implementing rules, both of which became effective on January 1, 2008. Under the EIT
Law, an enterprise established outside of China with &ldquo;de facto management bodies&rdquo; within China is considered a &ldquo;resident
enterprise,&rdquo; meaning that it can be treated in a manner similar to a Chinese enterprise for enterprise income tax purposes.
The implementing rules of the EIT Law define de facto management as &ldquo;substantial and overall management and control over
the production and operations, personnel, accounting, and properties&rdquo; of the enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 22, 2009,
the State Administration of Taxation of China issued the Notice Concerning Relevant Issues Regarding Cognizance of Chinese Investment
Controlled Enterprises Incorporated Offshore as Resident Enterprises pursuant to Criteria of de facto Management Bodies, or the
Notice, further interpreting the application of the EIT Law and its implementation to offshore entities controlled by a Chinese
enterprise or group. Pursuant to the Notice, an enterprise incorporated in an offshore jurisdiction and controlled by a Chinese
enterprise or group will be classified as a &ldquo;non-domestically incorporated resident enterprise&rdquo; if (i) its senior
management in charge of daily operations reside or perform their duties mainly in China; (ii) its financial or personnel decisions
are made or approved by bodies or persons in China; (iii) its substantial assets and properties, accounting books, corporate stamps,
board and shareholder minutes are kept in China; and (iv) at least half of its directors with voting rights or senior management
often reside in China. A resident enterprise would be subject to an enterprise income tax rate of 25% on its worldwide income
and must pay a withholding tax at a rate of 10% when paying dividends to its non-PRC shareholders. Because substantially all of
our operations and senior management are located within the PRC and are expected to remain so for the foreseeable future, we may
be considered a PRC resident enterprise for enterprise income tax purposes and therefore subject to the PRC enterprise income
tax at the rate of 25% on our worldwide income. However, it remains unclear as to whether the Notice is applicable to an offshore
enterprise controlled by a Chinese natural person. Therefore, it is unclear how tax authorities will determine tax residency based
on the facts of each case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the PRC tax authorities
determine that we are a &ldquo;resident enterprise&rdquo; for PRC enterprise income tax purposes, a number of unfavorable PRC
tax consequences could follow. First, we may be subject to the enterprise income tax at a rate of 25% on our worldwide taxable
income as well as PRC enterprise income tax reporting obligations. In our case, this would mean that income such as non-China
source income would be subject to PRC enterprise income tax at a rate of 25%. Currently, we do not have any non-China source income,
as we complete our sales, including export sales, in China. Second, under the EIT Law and its implementing rules, dividends paid
to us from our PRC subsidiaries would be deemed as &ldquo;qualified investment income between resident enterprises&rdquo; and
therefore qualify as &ldquo;tax-exempt income&rdquo; pursuant to the clause 26 of the EIT Law. Finally, it is possible that future
guidance issued with respect to the new &ldquo;resident enterprise&rdquo; classification could result in a situation in which
the dividends we pay with respect to our common stock, or the gain our non-PRC shareholders may realize from the transfer of our
common stock, may be treated as PRC-sourced income and may therefore be subject to a 10% PRC withholding tax. The EIT Law and
its implementing regulations are, however, relatively new and ambiguities exist with respect to the interpretation and identification
of PRC-sourced income, and the application and assessment of withholding taxes. If we are required under the EIT Law and its implementing
regulations to withhold PRC income tax on dividends payable to our non-PRC shareholders, or if non-PRC shareholders are required
to pay PRC income tax on gains on the transfer of their shares of common stock, our business could be negatively impacted and
the value of your investment may be materially reduced. Further, if we were treated as a &ldquo;resident enterprise&rdquo; by
PRC tax authorities, we would be subject to taxation in both China and such countries in which we have taxable income, and our
PRC tax may not be creditable against such other taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be exposed to liabilities
under the Foreign Corrupt Practices Act and Chinese anti-corruption law.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to
the U.S. Foreign Corrupt Practices Act (&ldquo;FCPA&rdquo;), and other laws that prohibit improper payments or offers of payments
to foreign governments and their officials and political parties by U.S. persons and issuers as defined by the statute for the
purpose of obtaining or retaining business. We are also subject to Chinese anti-corruption laws, which strictly prohibit the payment
of bribes to government officials. We have operations, agreements with third parties, and make sales in China, which may experience
corruption. Our activities in China create the risk of unauthorized payments or offers of payments by one of the employees, consultants
or distributors of our company, because these parties are not always subject to our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe
to date we have complied in all material respects with the provisions of the FCPA and Chinese anti-corruption law, our existing
safeguards and any future improvements may prove to be less than effective, and the employees, consultants or distributors of
our Company may engage in conduct for which we might be held responsible. Violations of the FCPA or Chinese anti-corruption law
may result in severe criminal or civil sanctions including&nbsp;personal liability for management, and we may be subject to other
liabilities, which could negatively affect our business, operating results and financial condition. In addition, the government
may seek to hold our Company liable for successor liability FCPA violations committed by companies in which we invest or that
we acquire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Uncertainties with respect to the
PRC legal system could adversely affect us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conduct all of
our business through our subsidiaries and variable interests entities in China. Our operations in China are governed by PRC laws
and regulations. Our PRC subsidiaries and variable interests entities are generally subject to laws and regulations applicable
to foreign investments in China and, in particular, laws and regulations applicable to wholly foreign-owned enterprises. The PRC
legal system is based on statutes. Prior court decisions may be cited for reference but have limited precedential value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since 1979, PRC legislation
and regulations have significantly enhanced the protections afforded to various forms of foreign investments in China. However,
China has not developed a fully integrated legal system and recently enacted laws and regulations may not sufficiently cover all
aspects of economic activities in China. In particular, because these laws and regulations are relatively new, and because of
the limited volume of published decisions and their nonbinding nature, the interpretation and enforcement of these laws and regulations
involve uncertainties. In addition, the PRC legal system is based in part on government policies and internal rules (some of which
are not published on a timely basis or at all) that may have a retroactive effect. As a result, we may not be aware of our violation
of these policies and rules until sometime after the violation. In addition, any litigation in China may be protracted and result
in substantial costs and diversion of resources and management attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, and as
discussed above in &ldquo;Risk Factors&mdash;Proposed legislation in the PRC could adversely affect our corporate structure, corporate
governance and business operations,&rdquo; MOFCOM, released in January 2015 a discussion draft of the proposed Foreign Investment
Law, which, if enacted, would replace existing laws regulating foreign investments in China with a uniform law. The proposed legislation
could affect a wide range of foreign entities, including our Company, and investments generally in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PRC regulation of
loans and direct investment by offshore holding companies to PRC entities may delay or prevent us from using the proceeds of this
offering to make loans or additional capital contributions to our PRC subsidiaries, which could materially and adversely affect
our liquidity and our ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In utilizing the proceeds
of this offering in the manner described in &ldquo;Use of Proceeds,&rdquo; as an offshore holding company of our PRC operating
subsidiaries, we may make loans to our PRC subsidiaries, or we may make additional capital contributions to our PRC subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any loans to our PRC
subsidiaries, and the repayments thereof, are subject to PRC regulations. For example, loans by us to our subsidiaries in China,
which are foreign invested entities (&ldquo;FIEs&rdquo;), to finance their activities cannot exceed statutory limits and must
be registered with the State Administration of Foreign Exchange, or SAFE. On August 29, 2008, SAFE promulgated Circular 142, a
notice regulating the conversion by a foreign-invested company of foreign currency into RMB by restricting how the converted RMB
may be used. The notice requires that RMB converted from the foreign currency-denominated capital of a foreign-invested company
may only be used for purposes within the business scope approved by the applicable governmental authority and may not be used
for equity investments within the PRC unless such investments are otherwise provided for in the business scope. The foreign currency-denominated
capital shall be verified by an accounting firm before converting into RMB. In addition, SAFE strengthened its oversight over
the flow and use of RMB funds converted from the foreign currency-denominated capital of a foreign-invested company. To convert
such capital into RMB, the foreign-invested company must report the use of such RMB to the bank, and the RMB must be used to the
reported purposes. According to Circular 142, change of the use of such RMB without approval is prohibited. In addition, such
RMB may not be used to repay RMB loans if the proceeds of such loans have not yet been used. Violations of Circular 142 may result
in severe penalties, including substantial fines as set forth in the Foreign Exchange Administration Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, SAFE
promulgated Circular 59 on November 19, 2010, requiring the governmental authority to closely examine the authenticity of settlement
of net proceeds from offshore offerings. In particular, any net proceeds settled from offshore offerings must be applied in the
manner described in the offering documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 10, 2013, SAFE
released Circular 21, which came into effect on May 13, 2013. According to Circular 21, SAFE has simplified the foreign exchange
administration procedures with respect to the registration, account openings and conversions, settlements of FDI-related foreign
exchange, as well as fund remittances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Circular 142, Circular
59 and Circular 21 may significantly limit our ability to convert, transfer and use the net proceeds from this offering and any
offering of additional equity securities in China, which may adversely affect our liquidity and our ability to fund and expand
our business in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also decide
to finance our subsidiaries by means of capital contributions. These capital contributions must be approved by the Ministry of
Commerce of China, or MOFCOM, or its local counterpart, which approval usually takes no more than 30 working days to complete.
We may not be able to obtain these government approvals on a timely basis, if at all, with respect to future capital contributions
by us to our PRC subsidiaries. If we fail to receive such approvals, we will not be able to use the proceeds of this offering
and capitalize our PRC operations, which could adversely affect our liquidity and our ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Governmental control of currency
conversion may affect the value of your investment by restricting our ability to pay dividends, even if profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC government
imposes controls on the convertibility of the RMB into foreign currencies and, in certain cases, the remittance of currency out
of China. We receive substantially all of our revenues in RMB. Under our current corporate structure, our income is primarily
derived from dividend payments from our PRC subsidiaries. Shortages in the availability of foreign currency may restrict the ability
of our PRC subsidiaries to remit sufficient foreign currency to pay dividends or other payments to us, or otherwise satisfy their
foreign currency denominated obligations. Under existing PRC foreign exchange regulations, payments of current account items,
including profit distributions, interest payments and expenditures from trade-related transactions can be made in foreign currencies
without prior approval from SAFE by complying with certain procedural requirements. However, approval from appropriate government
authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such
as the repayment of loans denominated in foreign currencies. The PRC government may also at its discretion restrict access in
the future to foreign currencies for current account transactions. If the foreign exchange control system prevents us from obtaining
sufficient foreign currency to satisfy our currency demands, we may not be able to pay dividends in foreign currencies to our
security-holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are a holding company and we
rely on dividend payments from our subsidiaries, which are subject to restrictions under PRC laws, for funding.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a holding company
incorporated in Delaware, and we operate our core businesses through our subsidiaries in the PRC and through various variable
interest entities, or VIEs, and agreements with third parties. Therefore, the availability of funds for us to pay dividends to
our shareholders and to service our indebtedness depends upon dividends received from these PRC subsidiaries. If our subsidiaries
incur debt or losses, their ability to pay dividends or other distributions to us may be impaired. As a result, our ability to
pay dividends and to repay our indebtedness will be restricted. PRC laws require that dividends be paid only out of the after-tax
profit of our PRC subsidiaries calculated according to PRC accounting principles, which differ in many aspects from generally
accepted accounting principles in other jurisdictions. PRC laws also require enterprises established in the PRC to set aside part
of their after-tax profits as statutory reserves. These statutory reserves are not available for distribution as cash dividends.
In addition, restrictive covenants in bank credit facilities or other agreements that we or our subsidiaries may enter into in
the future may also restrict the ability of our subsidiaries to pay dividends to us. These restrictions on the availability of
our funding may impact our ability to pay dividends to our Shareholders and to service our indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business may be materially and
adversely affected if any of our PRC subsidiaries declare bankruptcy or become subject to a dissolution or liquidation proceeding.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the SAFE&rsquo;s
Notice of the State Administration of Foreign Exchange on Further Improving and Adjusting Foreign Exchange Administration Policies
for Direct Investment, effective on December 17, 2012, and the Provisions for Administration of Foreign Exchange Relating to Inbound
Direct Investment by Foreign Investors, effective May 13, 2013, if any of our PRC subsidiaries undergoes a voluntary or involuntary
liquidation proceeding, prior approval from the SAFE for remittance of foreign exchange to our shareholders abroad is no longer
required, but we still need to conduct a registration process with the SAFE local branch. It is not clear whether &ldquo;registration&rdquo;
is a mere formality or involves the kind of substantive review process undertaken by SAFE and its relevant branches in the past.&nbsp;
If the review process is more substantive and stringent, it will be more time consuming and costly; thus diverting our management&rsquo;s
time and our revenues away from everyday operations.&nbsp; Additionally, if the registration requires a substantive review, it
will delay and could potentially deny our ability to remit our profits to our shareholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fluctuations in exchange rates could
adversely affect our business and the value of our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in the value
of the RMB against the U.S. dollar, Euro and other foreign currencies are affected by, among other things, changes in China&rsquo;s
political and economic conditions. Any significant revaluation of the RMB may have a material adverse effect on our revenues and
financial condition, and the value of, and any dividends payable on our shares in U.S. dollar terms. For example, to the extent
that we need to convert U.S. dollars we receive from our offering into RMB for our operations, appreciation of the RMB against
the U.S. dollar would have an adverse effect on RMB amount we would receive from the conversion. Conversely, if we decide to convert
our RMB into U.S. dollars for the purpose of paying dividends on our shares of common stock or for other business purposes, appreciation
of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amount available to us. In addition, fluctuations
of the RMB against other currencies may increase or decrease the cost of imports and exports, and thus affect the price-competitiveness
of our products against products of foreign manufacturers or products relying on foreign inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since July 2005, the
RMB is no longer pegged to the U.S. dollar. Although the People&rsquo;s Bank of China regularly intervenes in the foreign exchange
market to prevent significant short-term fluctuations in the exchange rate, the RMB may appreciate or depreciate significantly
in value against the U.S. dollar in the medium to long term. Moreover, it is possible that in the future PRC authorities may lift
restrictions on fluctuations in the RMB exchange rate and lessen intervention in the foreign exchange market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From June 30, 2016
to June 30, 2017, the PRC Government devalued its currency by approximately 2.1%, representing the largest yuan depreciation in
20 years. China weakened the value of RMB currency by 2.1% to 6.78 against the US dollar on June 30, 2017, from 6.64 against the
US dollar on June 30, 2016. On September 30, 2017, the value of RMB currency against the US dollar was 6.65. Concerns remain that
China&rsquo;s slowing economy, and in particular its exports, will need a stimulus that can only come from further cuts in the
exchange rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we become directly subject to
the recent scrutiny, criticism and negative publicity involving U.S.-listed Chinese companies, we may have to expend significant
resources to investigate and resolve the matter which could harm our business operations, this offering and our reputation and
could result in a loss of your investment in our stock, especially if such matter cannot be addressed and resolved favorably.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, U.S. public
companies that have substantially all of their operations in China, have been the subject of intense scrutiny, criticism and negative
publicity by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and negative
publicity has centered around financial and accounting irregularities, a lack of effective internal controls over financial accounting,
inadequate corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud. As a result
of the scrutiny, criticism and negative publicity, the publicly traded stock of many U.S. listed Chinese companies has sharply
decreased in value and, in some cases, has become virtually worthless or illiquid. Many of these companies are now subject to
shareholder lawsuits and SEC enforcement actions and are conducting internal and external investigations into the allegations.
It is not clear what effect this sector-wide scrutiny, criticism and negative publicity will have on our Company, our business
and this offering. If we become the subject of any unfavorable allegations, whether such allegations are proven to be true or
untrue, we will have to expend significant resources to investigate such allegations and/or defend the Company. If such allegations
are not proven to be groundless, our Company and business operations will be severely hampered and your investment in our stock
could be rendered worthless. Even if such allegations are groundless, this situation may be a major distraction to our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may face difficulties in protecting
your interests and exercising your rights as a shareholder since we conduct substantially all of our operations in China, and
almost all of our officers and directors reside outside the U.S.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we are incorporated
in Delaware, we conduct substantially all of our operations in China. All of our current officers and directors reside outside
the U.S. and substantially all of the assets of those persons are located outside of the U.S. It may be difficult for you to conduct
due diligence on the Company or such directors in your election of the directors and attend a shareholder meeting if the meeting
is held in China. We plan to have one shareholder meeting each year at a location to be determined, potentially alternating between
U.S. and China. As a result of all of the above, our public shareholders may have more difficulty in protecting their interests
through actions against our management, directors or major shareholders than would shareholders of a corporation doing business
entirely or predominantly within the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>DISCLOSURE REGARDING
FORWARD-LOOKING INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus and
the documents incorporated by reference herein contain forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.&nbsp;&nbsp;These forward-looking
statements are based on our current expectations and beliefs, including estimates and projections about our industry.&nbsp;&nbsp;Forward-looking
statements may be identified by use of terms such as &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo;
&ldquo;plans,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;believes&rdquo; and similar expressions, although some
forward-looking statements are expressed differently.&nbsp;&nbsp;Statements concerning our financial position, business strategy
and plans or objectives for future operations are forward-looking statements.&nbsp;&nbsp;These statements are not guarantees of
future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and may cause
actual results to differ materially from management&rsquo;s current expectations.&nbsp;&nbsp;Such risks and uncertainties include
those set forth herein under &ldquo;Risk Factors.&rdquo;&nbsp;&nbsp;The forward-looking statements in this prospectus speak only
as of the time they are made and do not necessarily reflect our outlook at any other point in time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as may be required
under the federal securities laws, we undertake no obligation to publicly update forward-looking statements, whether as a result
of new information, future events or otherwise.&nbsp;&nbsp;You are advised, however, to read any further disclosures we make on
related subjects in our filings with the SEC, including Form 10-K, Form 10-Q and Form 8-K reports.&nbsp;&nbsp;Also note that under
the caption &ldquo;Risk Factors,&rdquo; we provide a cautionary discussion of risks, uncertainties and possibly inaccurate assumptions
relevant to our business.&nbsp;&nbsp;These are factors that we think could cause our actual results to differ materially from
expected and historical results.&nbsp;&nbsp;Other factors besides those listed in &ldquo;Risk Factors,&rdquo; including factors
described as risks in our filings with the SEC, could also adversely affect us.&nbsp;&nbsp;For any forward-looking statements
contained in any document, we claim the protection of the safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in a prospectus supplement, we intend to use the net proceeds from the sale of the securities under this prospectus for general
corporate purposes. We may also use a portion of the net proceeds to acquire or invest in businesses and products that are complementary
to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this
prospectus. Pending the uses described above, we intend to invest the net proceeds in short-term, interest bearing, investment-grade
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>DETERMINATION OF
OFFERING PRICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offering price
of the securities may be determined by us or our sales agent from time to time in connection with the offering. We will provide
the offering price of securities in the supplement(s) to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our net tangible book
value as of September 30, 2017 was $3.14 per share of Common Stock&nbsp;&nbsp;. Net tangible book value per share of Common Stock
is determined by dividing our tangible net worth, which is tangible assets less liabilities, by the total number of shares of
our Common Stock outstanding. If we offer shares of our Common Stock, purchasers of our Common Stock in that offering may experience
immediate&nbsp;dilution in net tangible book value per share. The prospectus supplement relating to an offering of shares of our
Common Stock will set forth the information regarding any dilutive effect of that offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not Applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><B>DESCRIPTION OF SECURITIES
TO BE REGISTERED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of our capital stock (which includes a description of securities we may offer pursuant to the registration statement of which
this prospectus, as the same may be supplemented, forms a part) does not purport to be complete and is subject to and qualified
in its entirety by our certificate of incorporation, our bylaws and by the applicable provisions of Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized capital
stock consists of 105,000,000 shares of common stock, par value $0.001 per share, consisting of 100,000,000 shares of common stock
and 5,000,000 shares of preferred stock. The following description of our capital stock is intended as a summary only and is qualified
in its entirety by reference to our amended certificate of incorporation and bylaws, which have been filed previously with the
SEC, and applicable provisions of Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, directly or through
agents, dealers or underwriters designated from time to time, may offer, issue and sell, together or separately, up to $25,000,000
in the aggregate of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">common
                                         stock;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">preferred
                                         stock;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">secured
                                         or unsecured debt securities consisting of notes, debentures or other evidences of indebtedness
                                         which may be senior debt securities, senior subordinated debt securities or subordinated
                                         debt securities, each of which may be convertible into equity securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">warrants
                                         to purchase our securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">rights
                                         to purchase our securities; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">units
                                         comprised of, or other combinations of, the foregoing securities.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue the debt
securities as exchangeable for or convertible into shares of common stock, preferred stock or other securities. The preferred
stock may also be exchangeable for and/or convertible into shares of common stock, another series of preferred stock or other
securities. The debt securities, the preferred stock, the common stock and the warrants are collectively referred to in this prospectus
as the &ldquo;Securities.&rdquo; When a particular series of securities is offered, a supplement to this prospectus will be delivered
with this prospectus, which will set forth the terms of the offering and sale of the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of November 21,
2017, there were 21,034,072 shares of our common stock issued and outstanding, held of record by approximately 299 stockholders.
The outstanding shares of common stock are fully paid and non-assessable. The holders of common stock are entitled to one vote
for each share held of record on all matters submitted to a vote of the stockholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board is divided
into three classes, each of which will generally serve for a term of three years with only one class of directors being elected
in each year. The common stock has no cumulative voting rights, including with respect to the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to preferential
rights with respect to any future outstanding preferred stock, holders of common stock are entitled to receive ratably such dividends
as may be declared by our board of directors out of funds legally available therefore. As of the date of this prospectus, we do
not have any preferred stock outstanding nor do we have any classes of preferred stock designated. Pursuant to Section 281 of
Delaware General Corporation Law, in the event of our dissolution, the holders of common stock are entitled to the remaining assets
after payment of all liabilities of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock has
no preemptive or conversion rights or other subscription rights.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of
incorporation, as amended, empowers our board of directors, without action by our shareholders, to issue up to 5,000,000 shares
of preferred stock from time to time in one or more series, which preferred stock may be offered by this prospectus and supplements
thereto. As of the date of this prospectus, no shares of preferred stock were designated or issued and outstanding. Our board
may fix the rights, preferences, privileges and restrictions of our authorized but undesignated preferred shares, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">dividend
                                         rights and preferences over dividends on our common stock or any series of preferred
                                         stock;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         dividend rate (and whether dividends are cumulative);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">conversion
                                         rights, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">voting
                                         rights;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">rights
                                         and terms of redemption (including sinking fund provisions, if any);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">redemption
                                         price and liquidation preferences of any wholly unissued series of any preferred stock
                                         and the designation thereof of any of them; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
                                         increase or decrease the number of shares of any series subsequent to the issue of shares
                                         of that series but not below the number of shares then outstanding.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should refer to
the prospectus supplement relating to the series of preferred stock being offered for the specific terms of that series, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">title
                                         of the series and the number of shares in the series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         price at which the preferred stock will be offered;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         dividend rate or rates or method of calculating the rates, the dates on which the dividends
                                         will be payable, whether or not dividends will be cumulative or noncumulative and, if
                                         cumulative, the dates from which dividends on the preferred stock being offered will
                                         cumulate;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         voting rights, if any, of the holders of shares of the preferred stock being offered;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         provisions for a sinking fund, if any, and the provisions for redemption, if applicable,
                                         of the preferred stock being offered, including any restrictions on the foregoing as
                                         a result of arrearage in the payment of dividends or sinking fund installments;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         liquidation preference per share;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         terms and conditions, if applicable, upon which the preferred stock being offered will
                                         be convertible into our common stock, including the conversion price, or the manner of
                                         calculating the conversion price, and the conversion period;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         terms and conditions, if applicable, upon which the preferred stock being offered will
                                         be exchangeable for debt securities, including the exchange price, or the manner of calculating
                                         the exchange price, and the exchange period;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         listing of the preferred stock being offered on any securities exchange;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                         discussion of any material federal income tax considerations applicable to the preferred
                                         stock being offered;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         preemptive rights;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         relative ranking and preferences of the preferred stock being offered as to dividend
                                         rights and rights upon liquidation, dissolution or the winding up of our affairs;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         limitations on the issuance of any class or series of preferred stock ranking senior
                                         or equal to the series of preferred stock being offered as to dividend rights and rights
                                         upon liquidation, dissolution or the winding up of our affairs; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         additional rights, preferences, qualifications, limitations and restrictions of the series.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon issuance, the
shares of preferred stock will be fully paid and nonassessable, which means that its holders will have paid their purchase price
in full and we may not require them to pay additional funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any preferred stock
terms selected by our board of directors could decrease the amount of earnings and assets available for distribution to holders
of our common stock or adversely affect the rights and power, including voting rights, of the holders of our common stock without
any further vote or action by the stockholders. The rights of holders of our common stock will be subject to, and may be adversely
affected by, the rights of the holders of any preferred stock that may be issued by us in the future. The issuance of preferred
stock could also have the effect of delaying or preventing a change in control of our company or make removal of management more
difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this prospectus,
the term &ldquo;debt securities&rdquo; means the debentures, notes, bonds and other evidences of indebtedness that we may issue
from time to time. The debt securities will either be senior debt securities, senior subordinated debt or subordinated debt securities.
We may also issue convertible debt securities. Debt securities issued under an indenture (which we refer to herein as an Indenture)
will be entered into between us and a trustee to be named therein. It is likely that convertible debt securities will not be issued
under an Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will file as an
exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from a current report
that we file with the SEC, the form of Indenture and the form of each Indenture agreement, if any, relating to Indentures offered
under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Events of Default
Under the Indenture</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we provide
otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the following
are events of default under the indentures with respect to any series of debt securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         we fail to pay the principal or premium, if any, when due and payable at maturity, upon
                                         redemption or repurchase or otherwise;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         we fail to pay interest when due and payable and our failure continues for certain days;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         we fail to observe or perform any other covenant contained in the&nbsp;Securities of
                                         a Series&nbsp;or in this Indenture, and our failure continues for certain days after
                                         we receive written notice from the trustee or holders of at least certain percentage
                                         in aggregate principal amount of the outstanding&nbsp;debt securities&nbsp;of the applicable
                                         series. The written notice must specify the Default, demand that it be remedied and state
                                         that the notice is a &ldquo;Notice of Default&rdquo;;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         specified events of bankruptcy, insolvency or reorganization occur; and</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         any other event of default provided with respect to securities of that series, which
                                         is specified in a Board Resolution, a supplemental indenture hereto or an Officers&rsquo;
                                         Certificate as defined in the Form of Indenture.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We covenant in the
Form of Indenture to deliver a certificate to the trustee annually, within certain days after the close of the fiscal year, to
show that we are in compliance with the terms of the indenture and that we have not defaulted under the indenture. Nonetheless,
if we issue debt securities, the terms of the debt securities and the final form of indenture will be provided in a prospectus
supplement. Please refer to the prospectus supplement and the form of indenture attached thereto for the terms and conditions
of the offered debt securities. The terms and conditions may or may not include whether or not we must furnish periodic evidence
showing that an event of default does not exist or that we are in compliance with the terms of the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The statements and
descriptions in this prospectus or in any prospectus supplement regarding provisions of the Indentures and debt securities are
summaries thereof, do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all
of the provisions of the Indentures (and any amendments or supplements we may enter into from time to time which are permitted
under each Indenture) and the debt securities, including the definitions therein of certain terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
in a prospectus supplement, the debt securities will be direct secured or unsecured obligations of our company. The senior debt
securities will rank equally with any of our other unsecured senior and unsubordinated debt. The subordinated debt securities
will be subordinate and junior in right of payment to any senior indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue debt
securities from time to time in one or more series, in each case with the same or various maturities, at par or at a discount.
Unless indicated in a prospectus supplement, we may issue additional debt securities of a particular series without the consent
of the holders of the debt securities of such series outstanding at the time of the issuance. Any such additional debt securities,
together with all other outstanding debt securities of that series, will constitute a single series of debt securities under the
applicable Indenture and will be equal in ranking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should an indenture
relate to unsecured indebtedness, in the event of a bankruptcy or other liquidation event involving a distribution of assets to
satisfy our outstanding indebtedness or an event of default under a loan agreement relating to secured indebtedness of our company
or its subsidiaries, the holders of such secured indebtedness, if any, would be entitled to receive payment of principal and interest
prior to payments on the senior indebtedness issued under an Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prospectus Supplement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each prospectus supplement
will describe the terms relating to the specific series of debt securities being offered. These terms will include some or all
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         title of debt securities and whether they are subordinated, senior subordinated or senior
                                         debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         limit on the aggregate principal amount of debt securities of such series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         percentage of the principal amount at which the debt securities of any series will be
                                         issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         ability to issue additional debt securities of the same series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         purchase price for the debt securities and the denominations of the debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         specific designation of the series of debt securities being offered;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         maturity date or dates of the debt securities and the date or dates upon which the debt
                                         securities are payable and the rate or rates at which the debt securities of the series
                                         shall bear interest, if any, which may be fixed or variable, or the method by which such
                                         rate shall be determined;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         basis for calculating interest if other than 360-day year or twelve 30-day months;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         date or dates from which any interest will accrue or the method by which such date or
                                         dates will be determined;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         duration of any deferral period, including the maximum consecutive period during which
                                         interest payment periods may be extended;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                         the amount of payments of principal of (and premium, if any) or interest on the debt
                                         securities may be determined with reference to any index, formula or other method, such
                                         as one or more currencies, commodities, equity indices or other indices, and the manner
                                         of determining the amount of such payments;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         dates on which we will pay interest on the debt securities and the regular record date
                                         for determining who is entitled to the interest payable on any interest payment date;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         place or places where the principal of (and premium, if any) and interest on the debt
                                         securities will be payable, where any securities may be surrendered for registration
                                         of transfer, exchange or conversion, as applicable, and notices and demands may be delivered
                                         to or upon us pursuant to the applicable Indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         rate or rates of amortization of the debt securities, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         we possess the option to do so, the periods within which and the prices at which we may
                                         redeem the debt securities, in whole or in part, pursuant to optional redemption provisions,
                                         and the other terms and conditions of any such provisions;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         obligation or discretion, if any, to redeem, repay or purchase debt securities by making
                                         periodic payments to a sinking fund or through an analogous provision or at the option
                                         of holders of the debt securities, and the period or periods within which and the price
                                         or prices at which we will redeem, repay or purchase the debt securities, in whole or
                                         in part, pursuant to such obligation, and the other terms and conditions of such obligation;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         terms and conditions, if any, regarding the option or mandatory conversion or exchange
                                         of debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         period or periods within which, the price or prices at which and the terms and conditions
                                         upon which any debt securities of the series may be redeemed, in whole or in part at
                                         our option and, if other than by a board resolution, the manner in which any election
                                         by us to redeem the debt securities shall be evidenced;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         restriction or condition on the transferability of the debt securities of a particular
                                         series;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         portion, or methods of determining the portion, of the principal amount of the debt securities
                                         which we must pay upon the acceleration of the maturity of the debt securities in connection
                                         with any event of default if other than the full principal amount;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         currency or currencies in which the debt securities will be denominated and in which
                                         principal, any premium and any interest will or may be payable or a description of any
                                         units based on or relating to a currency or currencies in which the debt securities will
                                         be denominated;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">provisions,
                                         if any, granting special rights to holders of the debt securities upon the occurrence
                                         of specified events;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         deletions from, modifications of or additions to the events of default or our covenants
                                         with respect to the applicable series of debt securities, and whether or not such events
                                         of default or covenants are consistent with those contained in the applicable Indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         limitation on our ability to incur debt, redeem stock, sell our assets or other restrictions;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         application, if any, of the terms of the applicable Indenture relating to defeasance
                                         and covenant defeasance (which terms are described below) to the debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">what
                                         subordination provisions will apply to the debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         terms, if any, upon which the holders may convert or exchange the debt securities into
                                         or for our common stock, preferred stock&nbsp;&nbsp;or other securities or property;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                         we are issuing the debt securities in whole or in part in global form;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         change in the right of the trustee or the requisite holders of debt securities to declare
                                         the principal amount thereof due and payable because of an event of default;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         depositary for global or certificated debt securities, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         material federal income tax consequences applicable to the debt securities, including
                                         any debt securities denominated and made payable, as described in the prospectus supplements,
                                         in foreign currencies, or units based on or related to foreign currencies;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         right we may have to satisfy, discharge and defease our obligations under the debt securities,
                                         or terminate or eliminate restrictive covenants or events of default in the Indentures,
                                         by depositing money or U.S. government obligations with the trustee of the Indentures;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         names of any trustees, depositories, authenticating or paying agents, transfer agents
                                         or registrars or other agents with respect to the debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
                                         whom any interest on any debt security shall be payable, if other than the person in
                                         whose name the security is registered, on the record date for such interest, the extent
                                         to which, or the manner in which, any interest payable on a temporary global debt security
                                         will be paid if other than in the manner provided in the applicable Indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         the principal of or any premium or interest on any debt securities is to be payable in
                                         one or more currencies or currency units other than as stated, the currency, currencies
                                         or currency units in which it shall be paid and the periods within and terms and conditions
                                         upon which such election is to be made and the amounts payable (or the manner in which
                                         such amount shall be determined);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         portion of the principal amount of any debt securities which shall be payable upon declaration
                                         of acceleration of the maturity of the debt securities pursuant to the applicable Indenture
                                         if other than the entire principal amount;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         the principal amount payable at the stated maturity of any debt security of the series
                                         will not be determinable as of any one or more dates prior to the stated maturity, the
                                         amount which shall be deemed to be the principal amount of such debt securities as of
                                         any such date for any purpose, including the principal amount thereof which shall be
                                         due and payable upon any maturity other than the stated maturity or which shall be deemed
                                         to be outstanding as of any date prior to the stated maturity (or, in any such case,
                                         the manner in which such amount deemed to be the principal amount shall be determined);
                                         and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         other specific terms of the debt securities, including any modifications to the events
                                         of default under the debt securities and any other terms which may be required by or
                                         advisable under applicable laws or regulations.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
in the applicable prospectus supplement, the debt securities will not be listed on any securities exchange. Holders of the debt
securities may present registered debt securities for exchange or transfer in the manner described in the applicable prospectus
supplement. Except as limited by the applicable Indenture, we will provide these services without charge, other than any tax or
other governmental charge payable in connection with the exchange or transfer.</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Debt securities may
bear interest at a fixed rate or a variable rate as specified in the prospectus supplement. In addition, if specified in the prospectus
supplement, we may sell debt securities bearing no interest or interest at a rate that at the time of issuance is below the prevailing
market rate, or at a discount below their stated principal amount. We will describe in the applicable prospectus supplement any
special federal income tax considerations applicable to these discounted debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue debt
securities with the principal amount payable on any principal payment date, or the amount of interest payable on any interest
payment date, to be determined by referring to one or more currency exchange rates, commodity prices, equity indices or other
factors. Holders of such debt securities may receive a principal amount on any principal payment date, or interest payments on
any interest payment date, that are greater or less than the amount of principal or interest otherwise payable on such dates,
depending upon the value on such dates of applicable currency, commodity, equity index or other factors. The applicable prospectus
supplement will contain information as to how we will determine the amount of principal or interest payable on any date, as well
as the currencies, commodities, equity indices or other factors to which the amount payable on that date relates and certain additional
tax considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue warrants
for the purchase of our common stock, preferred stock or debt securities or any combination thereof. Warrants may be issued independently
or together with our common stock, preferred stock or debt securities and may be attached to or separate from any offered securities.
To the extent warrants that we issue are to be publicly-traded, each series of such warrants will be issued under a separate warrant
agreement to be entered into between us and a bank or trust company, as warrant agent. The warrant agent will act solely as our
agent in connection with such warrants. The warrant agent will not have any obligation or relationship of agency or trust for
or with any holders or beneficial owners of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will file as exhibits
to the registration statement of which this prospectus is a part, or will incorporate by reference from a current report on Form
8-K that we file with the SEC, forms of the warrant and warrant agreement, if any. The prospectus supplement relating to any warrants
that we may offer will contain the specific terms of the warrants and a description of the material provisions of the applicable
warrant agreement, if any. These terms may include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         title of the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         price or prices at which the warrants will be issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         designation, amount and terms of the securities or other rights for which the warrants
                                         are exercisable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         designation and terms of the other securities, if any, with which the warrants are to
                                         be issued and the number of warrants issued with each other security;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         aggregate number of warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         provisions for adjustment of the number or amount of securities receivable upon exercise
                                         of the warrants or the exercise price of the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         price or prices at which the securities or other rights purchasable upon exercise of
                                         the warrants may be purchased;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         applicable, the date on and after which the warrants and the securities or other rights
                                         purchasable upon exercise of the warrants will be separately transferable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                         discussion of any material U.S. federal income tax considerations applicable to the exercise
                                         of the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         date on which the right to exercise the warrants will commence, and the date on which
                                         the right will expire;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         maximum or minimum number of warrants that may be exercised at any time;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">information
                                         with respect to book-entry procedures, if any; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         other terms of the warrants, including terms, procedures and limitations relating to
                                         the exchange and exercise of the warrants.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exercise of Warrants.
Each warrant will entitle the holder of warrants to purchase the amount of securities or other rights, at the exercise price stated
or determinable in the prospectus supplement for the warrants. Warrants may be exercised at any time up to the close of business
on the expiration date shown in the applicable prospectus supplement, unless otherwise specified in such prospectus supplement.
After the close of business on the expiration date, if applicable, unexercised warrants will become void. Warrants may be exercised
in the manner described in the applicable prospectus supplement. When the warrant holder makes the payment and properly completes
and signs the warrant certificate at the corporate trust office of the warrant agent, if any, or any other office indicated in
the prospectus supplement, we will, as soon as possible, forward the securities or other rights that the warrant holder has purchased.
If the warrant holder exercises less than all of the warrants represented by the warrant certificate, we will issue a new warrant
certificate for the remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue rights
to purchase our securities. The rights may or may not be transferable by the persons purchasing or receiving the rights. In connection
with any rights offering, we may enter into a standby underwriting or other arrangement with one or more underwriters or other
persons pursuant to which such underwriters or other persons would purchase any offered securities remaining unsubscribed for
after such rights offering. Each series of rights will be issued under a separate rights agent agreement to be entered into between
us and one or more banks, trust companies or other financial institutions, as rights agent that we will name in the applicable
prospectus supplement. The rights agent will act solely as our agent in connection with the rights and will not assume any obligation
or relationship of agency or trust for or with any holders of rights certificates or beneficial owners of rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prospectus supplement
relating to any rights that we offer will include specific terms relating to the offering, including, among other matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date of determining
    the security holders entitled to the rights distribution;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the aggregate number
    of rights issued and the aggregate amount of securities purchasable upon exercise of the rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise price;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions to
    completion of the rights offering;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which
    the right to exercise the rights will commence and the date on which the rights will expire; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any applicable federal
    income tax considerations.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each right would entitle
the holder of the rights to purchase for cash the principal amount of securities at the exercise price set forth in the applicable
prospectus supplement. Rights may be exercised at any time up to the close of business on the expiration date for the rights provided
in the applicable prospectus supplement. After the close of business on the expiration date, all unexercised rights will become
void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If less than all of
the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons other than
our security holders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant
to standby arrangements, as described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units
consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence
each series of units by unit certificates that we may issue under a separate agreement. We may enter into unit agreements with
a unit agent. Each unit agent, if any, may be a bank or trust company that we select. We will indicate the name and address of
the unit agent, if any, in the applicable prospectus supplement relating to a particular series of units. Specific unit agreements,
if any, will contain additional important terms and provisions. We will file as an exhibit to the registration statement of which
this prospectus is a part, or will incorporate by reference from a current report that we file with the SEC, the form of unit
and the form of each unit agreement, if any, relating to units offered under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we offer any units,
certain terms of that series of units will be described in the applicable prospectus supplement, including, without limitation,
the following, as applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         title of the series of units;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">identification
                                         and description of the separate constituent securities comprising the units;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         price or prices at which the units will be issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         date, if any, on and after which the constituent securities comprising the units will
                                         be separately transferable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                         discussion of certain United States federal income tax considerations applicable to the
                                         units; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         other material terms of the units and their constituent securities.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions described
in this section, as well as those described under the description of &ldquo;Common Stock&rdquo;, &ldquo;Preferred Stock&rdquo;,
and &ldquo;Warrants&rdquo; will apply to each unit and to any Common Stock, Preferred Stock or warrant included in each unit,&nbsp;respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Provisions of the Delaware Law and Our Governing
Documents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.25pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Delaware Law</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to
Section 203 of the Delaware General Corporation Law (&ldquo;Section 203&rdquo;). In general, Section 203 prohibits a publicly
held Delaware corporation from engaging in &ldquo;business combination&rdquo; transactions with any &ldquo;interested stockholder&rdquo;
for a period of three years following the time that the stockholder became an interested stockholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
    to the time the stockholder became an interested stockholder, either the applicable business combination or the transaction
    which resulted in the stockholder becoming an interested stockholder is approved by the corporation&rsquo;s board of directors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
    owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for
    purposes of determining the voting stock outstanding (but not the voting stock owned by the interested stockholder) shares
    owned by directors who are also officers of the corporation and shares owned by employee stock plans in which the employee
    participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in
    a tender or exchange offer; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    or subsequent to the time that the stockholder became an interested stockholder, the business combination is approved by the
    corporation&rsquo;s board of directors and authorized at an annual or special meeting of stockholders by the affirmative vote
    of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A &ldquo;business
combination&rdquo; is defined to include, in general and subject to exceptions, a merger of the corporation with the interested
stockholder; a sale of 10% or more of the market value of the corporation&rsquo;s consolidated assets to the interested stockholder;
certain transactions that result in the issuance of the corporation&rsquo;s stock to the interested stockholder; a transaction
that has the effect of increasing the proportionate share of the corporation&rsquo;s stock owned by the interested stockholder;
and any receipt by the interested stockholder of loans, guarantees or other financial benefits provided by the corporation. An
&ldquo;interested stockholder&rdquo; is defined to include, in general and subject to exceptions, a person that (1) owns 15% or
more of the outstanding voting stock of the corporation or (2) is an &ldquo;affiliate&rdquo; or &ldquo;associate&rdquo; (as defined
in Section 203 of the DGCL) of the corporation and was the owner of 15% or more of the corporation&rsquo;s outstanding voting
stock at any time within the prior three year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Delaware corporation
may opt out of Section 203 with an express provision in its original certificate of incorporation or by an amendment to its certificate
of incorporation or bylaws expressly electing not to be governed by Section 203 and approved by a majority of its outstanding
voting shares. We have not opted out of Section 203. As a result, Section 203 could delay, deter or prevent a merger,&nbsp;change
of control&nbsp;or other takeover of our company that our stockholders might consider to be in their best interests, including
transactions that might result in a premium being paid over the market price of our common stock, and may also limit the price
that investors are willing to pay in the future for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent
and registrar for our common stock is Island Stock Transfer, LLC, 15500 Roosevelt Blvd. Suite 301, Clearwater, FL 33760, and their
telephone number is (727) 289-0010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NASDAQ Capital Market Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is
listed on the NASDAQ Capital Market under the symbol &ldquo;TYHT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
offered through this prospectus (i) to or through underwriters or dealers, (ii) directly to purchasers, including our affiliates,
(iii) through agents, or (iv) through a combination of any these methods. The securities may be distributed at a fixed price or
prices, which may be changed, market prices prevailing at the time of sale, prices related to the prevailing market prices, or
negotiated prices. The prospectus supplement will include the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the
    offering;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the names of any
    underwriters or agents;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the name or names
    of any managing underwriter or underwriters;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the purchase price
    of the securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any over-allotment
    options under which underwriters may purchase additional securities from us;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the net proceeds
    from the sale of the securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any delayed delivery
    arrangements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any underwriting
    discounts, commissions and other items constituting underwriters&rsquo; compensation;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any offering price;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any discounts or
    concessions allowed or reallowed or paid to dealers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any commissions
    paid to agents; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any securities exchange
    or market on which the securities may be listed.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sale Through Underwriters or Dealers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only underwriters
named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. If underwriters are
used in the sale, the underwriters will acquire the securities for their own account, including through underwriting, purchase,
security lending or repurchase agreements with us. The underwriters may resell the securities from time to time in one or more
transactions, including negotiated transactions. Underwriters may sell the securities in order to facilitate transactions in any
of our other securities (described in this prospectus or otherwise), including other public or private transactions and short
sales. Underwriters may offer securities to the public either through underwriting syndicates represented by one or more managing
underwriters or directly by one or more firms acting as underwriters. Unless otherwise indicated in the prospectus supplement,
the obligations of the underwriters to purchase the securities will be subject to certain conditions, and the underwriters will
be obligated to purchase all the offered securities if they purchase any of them. The underwriters may change from time to time
any offering price and any discounts or concessions allowed or reallowed or paid to dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If dealers are used
in the sale of securities offered through this prospectus, we will sell the securities to them as principals. They may then resell
those securities to the public at varying prices determined by the dealers at the time of resale. The prospectus supplement will
include the names of the dealers and the terms of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide in
the applicable prospectus supplement any compensation we will pay to underwriters, dealers or agents in connection with the offering
of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Direct Sales and Sales Through Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
offered through this prospectus directly. In this case, no underwriters or agents would be involved. Such securities may also
be sold through agents designated from time to time. The prospectus supplement will name any agent involved in the offer or sale
of the offered securities and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus
supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with
respect to any sale of those securities. The terms of any such sales will be described in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Delayed Delivery Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the prospectus
supplement indicates, we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to
purchase securities at the offering price under delayed delivery contracts. These contracts would provide for payment and delivery
on a specified date in the future. The contracts would be subject only to those conditions described in the prospectus supplement.
The applicable prospectus supplement will describe the commission payable for solicitation of those contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Making, Stabilization and Other Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the applicable
prospectus supplement states otherwise, other than our common stock, all securities we offer under this prospectus will be a new
issue and will have no established trading market. We may elect to list offered securities on an exchange or in the over-the-counter
market. Any underwriters that we use in the sale of offered securities may make a market in such securities, but may discontinue
such market making at any time without notice. Therefore, we cannot assure you that the securities will have a liquid trading
market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any underwriter may
also engage in stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the
Securities Exchange Act. Stabilizing transactions involve bids to purchase the underlying security in the open market for the
purpose of pegging, fixing or maintaining the price of the securities. Syndicate covering transactions involve purchases of the
securities in the open market after the distribution has been completed in order to cover syndicate short positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Penalty bids permit
the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate
member are purchased in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate
covering transactions and penalty bids may cause the price of the securities to be higher than it would be in the absence of the
transactions. The underwriters may, if they commence these transactions, discontinue them at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Agents, underwriters,
and dealers may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including
liabilities under the Securities Act. Our agents, underwriters, and dealers, or their affiliates, may be customers of, engage
in transactions with or perform services for us, in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in the applicable prospectus supplement, the validity of the securities offered by this prospectus, and any supplement thereto,
will be passed upon for us by Hunter Taubman Fischer &amp; Li, LLC, New York, NY. The legality of the securities for any underwriters,
dealers or agents will be passed upon by counsel as may be specified in the applicable prospectus supplement.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Wei, Wei &amp; Co.,
LLP (&ldquo;Wei&rdquo;), an independent registered public accounting firm, audited our financial statements included in our Annual
Report on Form 10-K for the year ended June 30, 2017, as set forth in their report included therein, which are incorporated by
reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference
in reliance on Wei&rsquo;s report, given on their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Material Changes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>WHERE YOU CAN FIND
ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&#9;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual, quarterly
and special reports, along with other information with the SEC. Our SEC filings are available to the public over the Internet
at the SEC&rsquo;s website at http://www.sec.gov; you can also find our filings on our company website: <U>http://shinecobiotech.mediaroom.com/index.php?s=2429&amp;o=0&amp;l=25</U>.
You may also read and copy any document we file at the SEC&rsquo;s Public Reference Room at 100 F Street, NE, Washington, D.C.
20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is
part of a registration statement on Form S-3 that we filed with the SEC to register the securities offered hereby under the Securities
Act of 1933, as amended. This prospectus does not contain all of the information included in the registration statement, including
certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the
SEC at the address listed above or from the SEC&rsquo;s internet site.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>INFORMATION INCORPORATED
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Securities and
Exchange Commission allows us to incorporate by reference the information we file with them under certain conditions, which means
that we can disclose important information to you by referring you to those documents. The information incorporated by reference
is considered to be a part of this prospectus and any information that we file subsequent to this prospectus with the Securities
and Exchange Commission will automatically update and supersede this information. The documents we are incorporating by reference
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Company&rsquo;s
                                         Annual Report on Form 10-K for the year ended June 30, 2017;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Company&rsquo;s
                                         Quarterly Report on Form 10-Q for the period ended September 30, 2017</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the Company&rsquo;s
                                         Current Reports on Form 8-K filed on October 27, 2017;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">the Company&rsquo;s
                                         Current Reports on Form 8-K filed on November 1, 2017;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">the Company&rsquo;s
                                         Current Reports on Form 8-K filed on November 13, 2017;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the
                                         Company&rsquo;s Current Reports on Form 8-K filed on November 16, 2017; and</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">the description
                                         of the Common Stock, $0.001 par value per share, contained in the Registrant&rsquo;s
                                         registration statement on Form 8-A filed with the Commission on May 13, 2016 pursuant
                                         to Section 12(b) of the Exchange Act and all amendments or reports filed by us for the
                                         purpose of updating those descriptions.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All documents filed
by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the initial filing date of this prospectus, through
the date declared effective, until the termination of the offering of securities contemplated by this prospectus shall be deemed
to be incorporated by reference into this prospectus. These documents that we file later with the Securities and Exchange Commission
and that are incorporated by reference in this prospectus will automatically update information contained in this prospectus or
that was previously incorporated by reference into this prospectus. You will be deemed to have notice of all information incorporated
by reference in this prospectus as if that information was included in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide to
any person, including any beneficial owner, to whom this prospectus is delivered, a copy of any or all of the information that
has been incorporated by reference in this prospectus but not delivered with this prospectus (excluding exhibits, unless the exhibits
are specifically incorporated), at no cost to the requesting party, upon request to us in writing or by telephone using the following
information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SHINECO, INC.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Room 1001, Building T5,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DaZu Square, Daxing District,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Beijing, People&rsquo;s Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Mr. Yuying Zhang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SHINECO, INC.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$25,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>November 21, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>PART II</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>INFORMATION NOT REQUIRED IN PROSPECTUS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Item 14. Other Expenses of Issuance and Distribution.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the costs and expenses payable by the registrant in connection with this offering, other than underwriting commissions
and discounts, all of which are estimated except for the SEC registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: justify">Securities and Exchange Commission registration fee</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,112.5</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Accounting fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,800</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Legal fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">10,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Miscellaneous expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">* Estimated expenses
are not presently known because they depend upon, among other things, the number of offerings that will be made pursuant to this
registration statement, the amount and type of securities being offered and the timing of such offerings; we cannot compute the
total until the exact expenses are known.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Item 15. Indemnification of Directors
and Officers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 102 of the
Delaware General Corporation Law allows a corporation to eliminate the personal liability of directors of a corporation to the
corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director breached
the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the
payment of a dividend or approved a stock repurchase in violation of the Delaware General Corporation Law or obtained an improper
personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Section 145
of the General Corporation Law of the State of Delaware, we can indemnify our directors and officers against liabilities they
may incur in such capacities, including liabilities under the Securities Act. Our certificate of incorporation provides that,
pursuant to Delaware law, our directors shall not be liable for monetary damages for breach of the directors&rsquo; fiduciary
duty of care to us and our stockholders. This provision in the certificate of incorporation does not eliminate the duty of care,
and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available
under Delaware law. In addition, each director will continue to be subject to liability for breach of the director&rsquo;s duty
of loyalty to us or our stockholders, for acts or omissions not in good faith or involving intentional misconduct or knowing violations
of the law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock
repurchases or redemptions that are unlawful under Delaware law. The provision also does not affect a director&rsquo;s responsibilities
under any other law, such as the federal securities laws or state or federal environmental laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 174 of the
Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful
payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either
absent when the unlawful actions were approved or dissented at the time, may avoid liability by causing his or her dissent to
such actions to be entered in the books containing minutes of the meetings of our board of directors at the time such action occurred
or immediately after such absent director receives notice of the unlawful acts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide
for the indemnification of our directors and officers to the fullest extent permitted by the Delaware General Corporation Law.
Our bylaws further provide that our Board of Directors has discretion to indemnify our agents and employees. We are required to
advance, prior to the final disposition of any proceeding, promptly on request, all expenses incurred by any director or executive
officer in connection with that proceeding on receipt of an undertaking by or on behalf of that director or executive officer
to repay those amounts if it should be determined ultimately that he or she is not entitled to be indemnified under the bylaws
or otherwise. We are not, however, required to advance any expenses in connection with any proceeding if our Board determines,
pursuant to Delaware law, that the claimant has not met the standards of conduct which make it permissible under the Delaware
General Corporation Law for the corporation to indemnify the claimant for the amount claimed.</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of
this prospectus, we have not entered into any indemnification agreement with our directors or officers.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our directors
and officers are covered under directors&rsquo; and officers&rsquo; liability insurance policies maintained by us, subject to
the limits of the policies, insuring such persons against various liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant
pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Item 16. Exhibits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents
are filed as exhibits to this registration statement, including those exhibits incorporated herein by reference to a prior filing
under the Securities Act or the Exchange Act, as indicated in parentheses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; width: 89%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of Document</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indenture(1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Debt Securities (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agreement, if any, including
    form of Warrant (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Preferred Stock Certificate of Designation
    (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Right Certificate (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv479787_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv479787_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Hunter Taubman Fischer &amp; Li,
    LLC&nbsp;*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv479787_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv479787_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Wei, Wei &amp; Co., LLP *</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv479787_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv479787_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Hunter Taubman Fischer &amp; Li,
    LLC (included in Exhibit 5.1)*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included in Part II of this
    Registration Statement)*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement of Eligibility of trustee on Form
    T-1+</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD><P STYLE="margin: 0pt 0">To be filed pursuant to Rule 305(b)(2) of the Trust Indenture Act, if applicable.</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If applicable,
    to be filed by amendment or by a report filed under the Securities Exchange Act of 1934, as amended, and incorporated herein
    by reference.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Item 17. Undertakings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The undersigned registrant
                                         hereby undertakes:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">To file, during
                                         any period in which offers or sales are being made, a post-effective amendment to this
                                         registration statement:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering
price set forth in the &quot;Calculation of Registration Fee&quot; table in the effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>provided, however,</I>&nbsp;Paragraphs
(a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the registration statement is on Form S-3 or Form F-3 and
the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or
furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that
are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b)
that is part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at
the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(A)&nbsp;Each prospectus
filed by the registrant pursuant to Rule 424(b)(3)shall be deemed to be part of the registration statement as of the date the
filed prospectus was deemed part of and included in the registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(B)&nbsp;Each prospectus
required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B
relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required
by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of
the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That,
for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) Any preliminary
prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Any free writing
prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned
registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) The portion
of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That
for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant
to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
supplement the prospectus, after the expiration of any subscription period, to set forth the results of any subscription offer,
the transactions by the underwriters during any subscription period, the amount of unsubscribed securities to be purchased by
the underwriters, and the terms of any subsequent reoffering thereof. If any public offering by the underwriters is to be made
on terms differing from those set forth on the cover page of the prospectus, a post-effective amendment will be filed to set forth
the terms of such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant
of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, Shineco, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Beijing on November 21, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHINECO, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Yuying
    Zhang</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuying Zhang</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_001"></A>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW BY ALL MEN BY
THESE PRESENTS that each person whose signature appears below hereby constitutes and appoints Yuying Zhang and Sai (Sam) Wang,
and each of them acting singly, as his true and lawful attorney-in-fact and agent with full power of substitution and resubstitution,
to act, without the other, for him and in his name, place and stead, in any and all capacities, to sign any or all amendments
(including post-effective amendments) to this Registration Statement, including any subsequent registration statement for the
same offering that may be filed under Rule 462(b), and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority
to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents
and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or
any of them, their substitute may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the
dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 35%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Yuying Zhang</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuying Zhang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sai (Sam) Wang</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial
    Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sai (Sam) Wang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jiping
    Chen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiping Chen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ying
    (Teresa) Zhang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ying (Teresa) Zhang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Yajun
    Shi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yajun Shi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Leiger
    Yongmin Yang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leiger Yongmin Yang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Hua
    Yang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hua Yang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tv479787_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>HUNTER TAUBMAN
FISCHER&amp; LI, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">1450 Broadway, 26<SUP>th</SUP>&nbsp;Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">New York, NY 10018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Tel. No: 212-530-2208</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Fax No: 212-202-6380</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>www.htflawyers.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 21, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shineco, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Room 1001, Building T5, DaZu Square,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daxing District, Beijing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">People&rsquo;s Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: Registration Statement on Form S-3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">You have requested
our opinion with respect to the offer and sale by you, Shineco, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
pursuant to a Registration Statement (the &ldquo;<B>Registration Statement</B>&rdquo;) on Form S-3 under the Securities Act of
1933, as amended (the &ldquo;<B>Act</B>&rdquo;), of up to $25,000,000 amount of (i)&nbsp;shares of common stock, par value $0.001
per share, of the Company (the &ldquo;<B>Common Stock</B>&rdquo;), (ii)&nbsp;shares of one or more series of preferred stock,
par value $0.001 per share, of the Company (the &ldquo;<B>Preferred Stock</B>&rdquo;), (iii)&nbsp;one or more debt securities
of the Company (the &ldquo;<B>Debt Securities</B>&rdquo;), (iv)&nbsp;warrants to purchase Common Stock or Preferred Stock (the
&ldquo;<B>Warrants</B>&rdquo;), (v) rights to purchase Common Stock, Preferred Stock or Debt Securities (the &ldquo;<B>Rights</B>&rdquo;),
and (v)&nbsp;units comprised of one or more of shares of Common Stock, shares of Preferred Stock, Debt Securities, Warrants and
Rights (the &ldquo;<B>Units</B>&rdquo; and, collectively with the Common Stock, Preferred Stock, Debt Securities, Warrants, and
Rights, the &ldquo;<B>Securities</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In rendering the opinions
set forth below, we have examined originals or copies certified or otherwise identified to our satisfaction of such documents
and corporate and public records as we deem necessary as a basis for the opinion hereinafter expressed. With respect to such examination,
we have assumed the genuineness of all signatures appearing on all documents presented to us as originals, and the conformity
to the originals of all documents presented to us as conformed or reproduced copies. Where factual matters relevant to such opinion
were not independently established, we have relied upon certificates of executive officers and responsible employees and agents
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">For purposes of this
opinion letter, we have also assumed that (a)&nbsp;the Registration Statement, and any amendments thereto (including post-effective
amendments), will have become effective and such effectiveness will not have been terminated or rescinded, (b)&nbsp;a prospectus
supplement will have been prepared and filed with the Securities and Exchange Commission describing the Securities offered thereby,
(c)&nbsp;all Securities will be offered, issued and sold in compliance with applicable federal and state securities laws and in
the manner stated in the Registration Statement and the appropriate prospectus supplement, (d)&nbsp;any definitive purchase, underwriting
or similar agreement with respect to any Securities offered will have been duly authorized and validly executed and delivered
by the Company and the other parties thereto, (e)&nbsp;any securities issuable upon exercise of any Securities being offered will
have been duly authorized, created and, if appropriate, reserved for issuance upon such exercise, (f)&nbsp;at the time of any
offering or sale of any shares of Common Stock or Preferred Stock or Warrants to purchase shares of Common Stock or Preferred
Stock, there will be sufficient shares of Common Stock or Preferred Stock, as applicable, authorized and unissued under the Company&rsquo;s
then operative certificate of incorporation, as amended (the &ldquo;<B>Certificate of Incorporation</B>&rdquo;) and not otherwise
reserved for issuance, (g)&nbsp;at the time of issuance of the Securities, the Company validly exists and is duly qualified and
in good standing under the laws of its jurisdiction of incorporation, and has the necessary corporate power for such issuance,
(h)&nbsp;at the time of issuance of the Securities, the Certificate of Incorporation and then operative bylaws of the Company,
as amended (the &ldquo;<B>Bylaws</B>&rdquo; and collectively with the Certificate of Incorporation, the &ldquo;<B>Charter Documents</B>&rdquo;)
are in full force and effect and have not been amended, restated, supplemented or otherwise altered, and there has been no authorization
of any such amendment, restatement, supplement or other alteration, in either case since the date hereof, (i)&nbsp;any applicable
Indenture relating to the issuance of the Debt Securities and any Warrant Agreement (defined below) or Unit Agreement (defined
below) has been duly authorized, executed and delivered by the parties thereto (other than the Company) and constitute legally
valid and binding obligations of the parties thereto (other than the Company), enforceable against each of them in accordance
with their respective terms, and (j)&nbsp;that the terms, execution and delivery of the Securities (i)&nbsp;do not result in breaches
of, or defaults under, agreements or instruments to which the Company is bound or violations of applicable statutes, rules, regulations
or court or governmental orders, and (ii)&nbsp;comply with any applicable requirement or restriction imposed by any court or governmental
body having jurisdiction over the Company. We have further assumed the legal capacity of natural persons, and we have assumed
that each party to the documents we have examined or relied on (other than the Company) has the legal capacity or authority and
has satisfied all legal requirements that are applicable to that party to the extent necessary to make such documents enforceable
against that party. We have not verified any of the foregoing assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We do not express
any opinion as to matters arising under the laws of any jurisdiction other than the United States federal securities laws, the
Delaware General Corporation Law and the Laws of the State of New York (collectively, the &ldquo;Laws&rdquo;). We are not members
of the Bar of the State of Delaware and have not obtained any opinions of local counsel. Insofar as the opinions expressed herein
relate to matters of the United States federal securities laws or regulations or matters of Delaware General Corporation Law,
we have relied exclusively on the latest standard compilations of such statutes and laws as reproduced in commonly accepted unofficial
publications available to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Based upon and subject
to the foregoing and the other matters set forth herein, it is our opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in; text-indent: 0.5in; text-align: justify">(1)&nbsp;&nbsp;&nbsp;With
respect to shares of Common Stock offered under the Registration Statement, when (a)&nbsp;the Company has taken all necessary
action to authorize and approve the issuance thereof and related matters, and (b)&nbsp;certificates representing the shares of
Common Stock have been duly executed, countersigned, registered and delivered, or if uncertificated, valid book-entry notations
have been made in the share register of the Company, in each case in accordance with the Charter Documents, either (i)&nbsp;against
payment therefor in an amount not less than the par value thereof or such other consideration determined by the Company&rsquo;s
Board of Directors and permitted under the Delaware General Corporation Law and in the manner contemplated by the Registration
Statement and/or the applicable prospectus supplement and in accordance with the provisions of the applicable definitive purchase,
underwriting or similar agreement, if any, approved by the Company or (ii)&nbsp;upon exercise of any other Security in accordance
with the terms of such Security or the instrument governing such Security as approved by the Company, for the consideration approved
by the Company (in an amount not less than the par value thereof or such other consideration determined by the Company&rsquo;s
Board of Directors and permitted under the Delaware General Corporation Law), the shares of Common Stock will be duly authorized,
validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">(2)&nbsp;&nbsp;&nbsp;With
respect to shares of one or more series of Preferred Stock offered under the Registration Statement, when (a)&nbsp;the Company
has taken all necessary action to authorize and approve the issuance thereof and related matters, including the adoption of an
appropriate amendment to the Company&rsquo;s Certificate of Incorporation relating to such series of Preferred Stock which has
been properly filed with the Secretary of State of the State of Delaware, and (b)&nbsp;certificates representing the shares of
Preferred Stock have been duly executed, countersigned, registered and delivered, or if uncertificated, valid book-entry notations
have been made in the share register of the Company, in each case in accordance with the Charter Documents, either (i)&nbsp;against
payment therefor in an amount not less than the par value thereof or such other consideration determined by the Company&rsquo;s
Board of Directors and permitted under the Delaware General Corporation Law and in the manner contemplated by the Registration
Statement and/or the applicable prospectus supplement and in accordance with the provisions of the applicable definitive purchase,
underwriting or similar agreement, if any, approved by the Company or (ii)&nbsp;upon conversion, exchange, redemption or exercise
of any other Security in accordance with the terms of such Security or the instrument governing such Security as approved by the
Company, for the consideration approved by the Company (in an amount not less than the par value thereof or such other consideration
determined by the Company&rsquo;s Board of Directors and permitted under Chapter the Delaware General Corporation Law), the shares
of Preferred Stock will be duly authorized, validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">(3)&nbsp;&nbsp;&nbsp;With
respect to Debt Securities, when (a)&nbsp;an applicable Indenture, if any, or any necessary amendment or supplement thereto or
other agreement in respect thereof, if any, has been duly authorized and validly executed and delivered by the Company and the
trustee thereunder, (b)&nbsp;any applicable Indenture, if required, has been duly qualified under the Trust Indenture Act of 1939,
as amended, if qualification is required thereunder, (c)&nbsp;the specific terms and the issuance and sale of any particular Debt
Security have been duly established in accordance with the applicable Indenture, if any, or any necessary amendment thereto or
other agreement in respect thereof, if any, and authorized by all necessary action of the Company, and (d)&nbsp;any such Debt
Security has been duly executed, issued, authenticated (if required) and delivered by or on behalf of the Company as contemplated
by the Registration Statement and/or the applicable prospectus supplement either (i)&nbsp;against payment therefor in accordance
with the provisions of the applicable Indenture and/or any other agreement or instrument binding upon the Company and the provisions
of the applicable definitive purchase, underwriting or similar agreement approved by the Company and in the manner contemplated
by the Registration Statement and/or the applicable prospectus supplement or (ii)&nbsp;upon conversion, exchange, redemption or
exercise of any other Security in accordance with the terms of such Security or the instrument governing such Security as approved
by the Company, for the consideration approved by the Company, such Debt Securities will constitute valid and binding obligations
of the Company, enforceable against the Company in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">(4)&nbsp;&nbsp;&nbsp;With
respect to Warrants offered under the Registration Statement, when (a)&nbsp;the Company has taken all necessary action to authorize
and approve the creation of and the issuance and terms of the Warrants, the terms of the offering thereof and related matters,
(b)&nbsp;a warrant agreement in respect thereof (a &ldquo;<B>Warrant Agreement</B>&rdquo;) has been duly authorized, executed
and delivered by the Company in accordance with applicable law and (c)&nbsp;the Warrants have been duly executed and delivered
against payment therefor in accordance with the provisions of the Warrant Agreement and in the manner contemplated by the Registration
Statement and/or the applicable prospectus supplement (assuming the securities issuable upon exercise of the Warrants have been
duly authorized and reserved for issuance by all necessary corporate action and in accordance with applicable law), the Warrants
will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">(5)&nbsp;&nbsp;&nbsp;With
respect to the Rights, assuming that the Rights are issued pursuant to one or more rights agreements (each, a &ldquo;<B>Right
Agreement</B>&rdquo;) to be entered into between the Company and one or more banks, trust companies or other financial institutions
as identified in the applicable Rights Agreement, and the holders from time to time of the Rights, and assuming that the issuance
and terms of any Rights and the terms of the offering thereof have been duly authorized, when (a)&nbsp;the Rights Agreement or
Rights Agreements relating to such Rights have been duly authorized, executed and delivered by the Company and the rights agent
appointed by the Company and (b)&nbsp;such Rights or certificates representing such Rights have been duly executed, authenticated,
issued, paid for and delivered as contemplated in the Registration Statement and any applicable prospectus supplement relating
thereto, and in accordance with any underwriting agreement, purchase or similar agreement, such Rights will constitute valid and
binding obligations of the Company, enforceable against the Company in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">(6)&nbsp;&nbsp;&nbsp;With
respect to Units, assuming that (a)&nbsp;any Debt Securities that form a part of such Units constitute valid and binding obligations
of the Company, enforceable against the Company in accordance with their terms, as contemplated in numbered paragraph 3 above,
(b)&nbsp;any Warrants that form a part of such Units constitute valid and binding obligations of the Company in accordance with
their terms, as contemplated in numbered paragraph 4 above, and (c)&nbsp;any shares of Common Stock or Preferred Stock that form
a part of such Units are validly issued, fully paid and nonassessable, as contemplated in numbered paragraphs 1 and 2 above, respectively,
when (i)&nbsp;the Company has taken all necessary corporate action to approve the creation of and the issuance and terms of the
Units (including the Securities which comprise such Units), the terms of the offering thereof and related matters, (ii)&nbsp;any
applicable unit agreement has been duly authorized, executed and delivered by the Company in accordance with applicable law (a
&ldquo;<B>Unit Agreement</B>&rdquo;), and (iii)&nbsp;the Units or certificates representing the Units, as the case may be, have
been delivered against payment therefor in accordance with the provisions of any applicable Unit Agreement or purchase or similar
agreement approved by the Company and in the manner contemplated by the Registration Statement and/or the applicable prospectus
supplement, the Units will constitute valid and binding obligations of the Company, enforceable against the Company in accordance
with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We express no opinions
regarding (i)&nbsp;the validity or enforceability of any provisions that purport to waive or not give effect to rights or notices,
defenses, subrogation or other rights or benefits that cannot be effectively waived under applicable law, (ii)&nbsp;the enforceability
of indemnification provisions to the extent they purport to relate to liabilities resulting from or based upon negligence or any
violation of federal or state securities or blue sky laws, (iii)&nbsp;any provision for liquidated damages, default interest,
late charges, monetary penalties, make-whole premiums or other economic remedies to the extent such provisions are deemed to constitute
a penalty, (iv)&nbsp;consents to, or restrictions upon, governing law, jurisdiction, venue, arbitration, remedies or judicial
relief, (v)&nbsp;any provision requiring the payment of attorneys&rsquo; fees, where such payment is contrary to law or public
policy, (viii)&nbsp;provisions for exclusivity, election or cumulation of rights or remedies, (ix)&nbsp;provisions authorizing
or validating conclusive or discretionary determinations, (x)&nbsp;grants of setoff rights, (xi)&nbsp;the availability of equitable
remedies to any person or entity including, but not limited to, specific performance and injunctive relief; (xii)&nbsp;the effect
of bankruptcy, reorganization, insolvency, fraudulent conveyance, fraudulent transfer, moratorium and other similar laws or equitable
principles affecting creditors&rsquo; rights or remedies (whether applied by a court of law or equity), (xiii)&nbsp;the effect
of applicable law and court decisions which may hereafter limit or render unenforceable certain rights or remedies of any person
or entity and (xiv)&nbsp;the severability, if invalid, of provisions to the foregoing effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We confirm that we
furnish no opinion with respect to the truth and accuracy or the completeness of the Registration Statement. The opinions we express
herein are limited to matters involving the Laws and are further expressly limited to the matters set forth herein and we render
no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Securities or any of the
Company&rsquo;s other securities. Accordingly, no provision of this letter is intended to be, nor shall any such provision be
construed as, an opinion concerning any matter not specified in this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We hereby consent
to the use of this opinion as Exhibit 5.1 to the Registration Statement, and to the use of our name as your counsel under &ldquo;Legal
Matters&rdquo; in the Prospectus constituting a part of the Registration Statement. In giving this consent, we do not thereby
concede that we come within the categories of persons whose consent is required by the Act or the General Rules and Regulations
promulgated thereunder. The opinion specified in this letter is as of the date of this letter, and we assume no obligation to
update or supplement any of the opinions set forth herein to reflect any changes of law or fact that may occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 196.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Hunter Taubman Fischer &amp; Li, LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tv479787_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B><IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; padding: 0; font-size: 10pt; text-indent: 0"><IMG SRC="image_002.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 76%; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 11pt"><B>CONSENT
        OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&nbsp;</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the inclusion in this registration statement on Form S-3 of our report dated October 13, 2017 relating
to the consolidated financial statements of Shineco, Inc. as of June 30, 2017 and 2016 and for the years ended 2017 and 2016.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also consent to the reference to our firm under the caption &ldquo;Experts&rdquo; in such registration statement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><IMG SRC="image_003.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Flushing, New York</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 21, 2017&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B></B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "5 58# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH @FZH< XW=?3Y?\]_I7XC?\%@/^"E'Q^_X)YP_!W4O@[\ =$^-FA>/K?Q
MY<^-]1UNS\?&S\$6_A%?"KV=Q<ZEX0CFLM/@U.+6[T+-J[VL1DM'"2E4D#_M
MY)'OQSC&>V<YQ[CTK-O=(MM0BGMKV*VN[*ZC,-U8WEI#=VEU Z-'+;W,%QOB
MFMYD*F6)T(=XXV8LJ[#Z&28S Y9F^'Q^:9'@\_RZD[XG*Z\I4I8Q6Y>6=92A
MR\JU@U-:QBI/E;2SK1JSART:WL)_SVYN[VUUV_X<_B2M/^#J;]HB&YMI+_\
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MG@CQ?<32*DZ^-/A7J&L_#'Q9]IA'FO&UQX@\'S74 E?S9K'4K6\RZ.C3_O\
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M4[WXLZDY,7+/"-.^$-F0FT QJ8EEGSFW,PPS?#?_  :GA3\4OVXO,SL'PV^
MI(+ Q[D\4?%DQL8G?8\P(S#*T4CP$2>4\;2L)?Z_/B]\8?A]\"OAWXM^*WQ9
M\2P^!OAMX"TF77_&7C._AO9K'0M)2[LK)[J[M=*LM0U1XWN+^$(+6SNG\N.6
M48$>#Y_B+0X*X$\0LQX4RCPYR?-,)@*N44\)/%9KQCB\;B)YQ@,)BH1J4:&>
M3EKB\15HT;T4XTH4^97E%N\%4QF*P5/%5,=[.ZGS+E@E'DJ2@GLI:QC=VV;W
M23/QE_X)T?\ !6+XX_MZV7[4VE6_[(>G> OB?^SSX'TS5=$\#/\ $\&3QY\1
M-57Q9;:=\/\ 57\6^%_!Y\"7%QK6@W%M=ZEK5Q>V6GO=-%=7ME/MDC^._P!H
MO_@X!_;%_8]\8Z+\/?VH/^"9.E_";QAKVA0^)=+TZ?\ :<T/Q%9:UH3WUS87
M6LZ#KG@KP)XNT"^MX]0AELRT6N2RI-"?,ACCDMY9?VW_ &-?V6?@/\*?%G[0
M'[5GP*\7^(/&%I^WIXD\%?'34=6OY;"3PO\ 8KS0M0U;0K_P/:PZ/I.K6FB>
M((O%%QK%R^LW%WJ-U*VG"5P+=II_YI_^#J^WAC^+/[$=VL48NKGX:?'B*>X\
MN,3R6]MXL^%TUI;R2*BR/#9O?7AMHF<PPM<SM#'$TTYEP\.LO\.N,_%.CPY_
MJ9AO]6<^P<,4H8BMGV%S3+\QR7A+!T\QI4,7A^(7.,(9I@Z^&K7C*%:DI.A.
M5&=-O;&UL3A<K]K"O>M!147RJS4JD82MHE\,F[]=O3[4_9C_ ."XG[??[9UM
MXON?V6/^"5.G?%RW\$20V?B34H?VK?"'@?1M'O-326XTC3;K7/B3X/\ !NCR
MZIJ$06<Z?87MY?1PN;V6V2U/F5_4<N\_?&-KG:<@[EPRJ>#UP03D#Z5_*#_P
M:N()?V=_VLU_B/QN\'JIDS(B,OP\AVNJ91EQYQ.(Y(I"R[C-AMH_K"KY+Q2P
M>59)QYGW#.3<.Y?D67Y%6I4:57"8W.,;B<<Z]##5[XR6:YACHQ=*EB,-4I+#
M1I:XFK"LZDH)4M<NG5J8*A5K5.><U)_"E:SVT2O_ %8****_/SL"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#_/3_P"#DGX9#P3_ ,%))/&$$96T^,7[/_PD\>/<9N&@;4] O/&_PJU&R5ID
M(_M"*U\":'?W B=83:7\$[*;N6Y:7X;_ ."2/Q&'PN_X*8?L4^(FD*0:U\<?
M#7PTNE 7$Z?%R._^&-K$Q<9 &K^*=+EPC*S&(#+#Y3^^7_!U;\,R$_8U^,\$
M#E86^*7PIU"9$BVJFHQ>&?&6BK,5?S%\E=$U:",A3&[W!!()4'^2WX<>++KP
M#\2/ASX\L)_LVH^!_B)X!\;:=.P8I!J'@[QAHOBBSG.R6,J\4VC*R.<J@,FY
MDRN[_13PO<>*? ?+<LJ356K4X2XGX:JU;*I;&X18C"46Z7-\5ZE*LJ3GHX<K
MG[W/'XO'4_JV<_S7JTY6MR]8+S[-[=;:VN_]>!1A IZ_."0 ,D+MW8 P-V-W
M'&"#WK\*?^#A3]I2?X(_\$X?'?@C2-4;3?&O[2/B+P[\&=#\B1([M/#-[?Q>
M)?B9+"BK]I\FY\!Z)J7A*>>V9+ZRO/%5O<6EQ:SP174/[B:+J=CK^C:3KNES
M"?3=<TZUUG3IU5E6:RU>TBO[27:X5QOM[B-OG"MS\RJ?E'\-'_!QM\5O$_[0
M/[>?P-_8V^&5P-7'PQ\&^%=*L]&M4D8S?''XZZVJ2V=Q!!,/M":;X-LOAFU@
M]N(4L9M8\71W#?:1M'\8>#/#D>)?$C),+CJ:I9;E,LSXGS^=1<T,)E/#."S"
MKBO:.7+&3CB\!@%&FYP<Y5O9QO[-NI]/F<W2P-H2M5Q-2A0AWC[12C*2_F:7
M32]]6C^98J$! /+EV;"^460E9!YL:X";IA,/LV!;PQ!;>"-+<"*O[1O^#6S]
MH?\ M;X6?M&?LN:EJ3OJ/@+Q=I/QG\(:<Y0#_A&_B!"OAKQ9Y'FAI)(;#Q1H
M&EZA?) R6]O)X@ADB"7E]>FZ_G__ ."O?[$6E_L&_M:VWPI\*VLEO\/O$GP<
M^%?B[P;++.9VO[G3O"MGX&\=WKS22M))JFN>._"&O>*=1A6.)!>>(G2Q22W6
M,KV?_!"G]H,?L[_\%*_@I?:A?)8^&/C7::Y^SOXH>618;:2Q^))T[4_"[22,
M,[X?B)X/\&?9I5!C9;U;=F5[N G^SO$VA@/$KP-S+-\L_?5(Y3@L[RMI*K-8
MC#PE2K3;C9QE%4*].K%)M-.+:<7;Y3+.?!YO3C5DZ?)*<*D)+^(V_=D[M6NG
M&5G>U]W>Y_I-3N62=&)(VH0HP,J6&Y=V. PRA.=X!RI# $?P8_\ !S=\2;WX
MA_MU_"_X,Z9<R3+\+O@EH>DV]GY;8@\4?%OQ;-J^I7,&Z*<33ZAIVG^$+012
MEK?S;&VC$6R6</\ WES(K1L)%^4B.(AE;YAO48V@98%C@$ JQ( SQ7^?7XUM
MKO\ ;;_X.+I-%"'6/#6B_MQ:9X;OK>XC>>S;P1^R/J<%IXSL)"I7?9Z[_P *
MD\411RQG:Q\0N+=F,]OO_E+Z/D7A>,<_XKQ5H8?@_@+,\YI\RT>9U<#B\%"G
MSMJ-*I)XE0C4:DU.<5R:\T?I\VDOJ\*,;2EB*M%)WLH\E:G4>FK>D;=$M6^Q
M_=A^SI\,K3X*_L^_!/X/65M'9V_PR^%7@/P/]E@:0Q17'ACPMIFF700R'S70
MWEM.V92S/NS)N8DU_-U_P=3?\F[_ +)__9<_%O\ ZK_4*_JK3<\";@1(WF,X
M(/WV;+XSR$W;B@Y.P =<9_E1_P"#J6ZMY?V>OV38XY4=F^-_BYD53G,<?P\F
MW.#G;L3=&&?)53- "0;B#?X/@S7E6\9>"<95G*K5QN;X^K6DDY+_ &K#\25*
MU=N[NJ;S!NS:YU27O14FXO,&UEN)ARV7L:=GW^72UDM^Y^+G_!$/X4?M\_%+
MQ_\ M$I^P9^U)X'_ &7]>\/^#_AK)\3=4\<>!?#OQ M/&>CZQX@\86_A33;'
M2/$WPY^(EA;S:+>67B"YDNX;;2KW?J5K#'-=V[W4=O\ I#_P5#_9H_X+:>#?
MV*_C%XK_ &C/V_\ X5?'SX$^']*TJ^^*7PU\)?#3P'\,-:U7PTVO:/9QWPU#
MPG\ O"-UKEG8ZW=Z'J.J:%+KVG!K6*]CB_M,/_9<W/?\&I;#_A;'[;R'EG^&
M_P !0NU2Q.[Q3\54!^53M ,B[F("JI+N0BLR_P!DWBKPGX;\:Z+JN@^*/#VB
M^+- UFQN-/U/P]K^E:9K>C:I922VSSV6HZ1K5M=:;J-C-<6-K+)9W=O)"Y@W
MC=YFQ_T_Q9\1<QX:\9<3.'#_  =CL-E-?A+'4I8WA?*\1FV-A0R_+\UY,5G>
M(IUJ]155B'0HSGAJGU;#JC24:E.BHOAR[!1K95"#JRBZJJW:DTHOVLHJT.;^
M[KK&_6[L>!_L0^5)^QI^R'-&ZRK)^RU^S^T<J.SJP_X5#X.>.0LS.9,H=R2,
M7=DD +,"<_RL?\'6G_)4_P!A\>GPW^/WY?\ "3_"7'^>_P!:_H+^"'[<>A^-
MO^"@7QR_X)_>!OAEH^C^#?V9?A3X;\3:EX_T?6+:RT^#6+^W\)6J^ =)\!6&
MCZ7I^B:9H$>OG1K2]M+J[^;1;R%K2)2MP?YXO^#JW6;.[^-7[%VB1RJU]I7P
MG^,NKW<:21MY=KXA\8^ K'3Y#"&,D9DF\,:FC3.HBG>!EB9C;RA/E?!#+L;E
M?C5PO#'8:6#KXO(L]SW#X&K)O%1RS.\CS',<NK3ARVA4K4*;;I2<9J"G5MIR
MRZLSE3GE<Y>T6O*MNOMH76ZU5M5;YL^MO^#5ZSNHOV<OVH[TAUM;OX[>&8XR
M%4B3[+\.[.*7!8'[LUQ;YP008\="X;^KJOY8?^#6E;2+]E']I"4&)9YOV@M/
M28E<MYB> ="^S"4*"?F#!(S@!AD*<BOZG001D=.?T.#^M?->,L_:^+G'TN:E
M>GFV'H.$)N4U[+*\HI\U1.$.3G^K<T5>5^:2;7LTY]&6V_L_"I._NR?WRT^7
MZW0M%%%?FYV!1110 44PNH8KDD@ D!6.,G S@$9/IUQSC'-(LL;$*K9)4-P&
M.%/0DXPN?]K!SQUH DHJ,RQ@9+<<\X., @$].F6'/0YX/6G@@YQV)!X(Y'U_
MSC!Z$4 +13!(A8J&!8=5YR,Y()'4 X.">"> <D4^@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#^>?_@Y-^&C^,_^":^J>.((XA=?!/XR
M?![QG=3/&78:/XN\13?!ZY@AD##R0^L_$#0;Z]D"3".WL2639NFB_P ^ZYC6
M>&5%)VM$6PZ[#);[-\RXR2CO$RQQ ;B&>3O&0W^I/_P4]^%?_"ZO^">G[7_P
MWA@$]]K/P&\8ZKHZ-"UR%\0>#K-?&GAZ;R003]FUSP_I]P&&=AB$KAPA%?Y;
M:2)/%;W*KE98DFC?!"RK/^_\Y(WW?NIA.)HE?(42F- L:(J_W1]%',Y8_A'/
M,C4[K*N*Z\L+"6OL:F<0BIN[NYQGBDJG)+FIQY>512;3^1XC3IXR-:&E5QG+
MFWUI\S3L[Q;T3V[7T/\ 4I_X)_\ QOTGQM_P3R_98^,WB?5K#3=)'[-7@C6_
M&&NZA>I#9:,O@GP@FF>,[W4[J5$6.VT2YT#4!J%Y)Y>/(GE>./85/\@__!(_
M1-?_ ."C?_!9[Q+^UGXPTB27PSX-\3?$']J+6+&^5[NTTN\NI[[P[\!O#5U=
M6\D(_M;PI>ZQX8UFTP8[:27X?72QVVVX9;3W7X=?MIS?"[_@V=NO"]CJLT?C
M;Q%\9?B7^QAX>F$\"7,<7Q!\9^)_C'K[NYD5S9Z3\'-=\4(RLCO)!:V]LQ\M
MU<_HS_P;(?LU/\+_ -D'Q[^T'XATG[)XD_:.^)=Z/#5W<96Y/PG^&UI'X8T)
M1%(I:&/5?B!)\1]5MX8'$4VA+X:N9H_M(D=_R&GE_P#J%PCXTYVXJGCL]XFQ
MGA]PYB(2<:F&E/'9EF.>0@_=4Z=?"RC3J0G&5[\M.T(GJ.I]=Q&4T9/F5+"T
ML755OBK<L?9R=K;.,GRI\K;=ULEYA_P=*_L]OXE^!'[/'[3.DVK?VC\'O'GB
M;X;^*M2MK>/S%\'?%JQT_4=*NM0F56FG@T'QEX)TRVTB&0B&T;Q3JZQRPOJ$
MIG_BCTW6]<\+:SIOB3PSJ$NC^)/#.L:=XD\.:E9Y$VD^(?#M_::MH.HVK9^6
M33=2L+.[MMA0I<6UE*&_T8+)_J1_\%(/@*O[4'[$'[3?P/M;-+SQ#XF^$7BC
M4O \;GE?B1X5MAXO^'6"4=O+G\::#HME=J"1)975S \5Q%,T+_Y9$;N\2/)&
MT3.BEHI$9)(@T8(B=9 &W(NU&W*-VTM\P(8_L'T7N(J6=\!YGPYBXQJT\FS3
M#X)8>25HY7FW-FKPTK)2FI5L36?M)-SBI*E"<815->5G^'G1QU/%;>ULU;36
M,8Q35K6T2>WGN?ZN/@7]IWPSXY_9)T+]KFSAM;+PIKWP'C^.US:-J#36VE6]
MIX(/B[6-$GOVMXRTVDW<5YH-S*]I _VS3[FY:TCD4VM?QU_\&U?P_P!1^,'_
M  4 ^-W[0&MI<WTOPU^%WB_Q7J&J7B+<O+XZ^/'C>>U@N;BXD9Y(M1UG3=)\
M>ZB]R0TLIBNLJPNY'A]'_9,_;@N;3_@W7_;:^'FH:FQ\8_ 759?@)H2,XN+Z
M3P-^U'XH\'V?A34K=G#-+_9-[X]^*.G0P2+(?L/@L2R22^8X'W=_P:Q_!F/P
MW^RM^T!\;9[1XKKXO?&'0_"NGW+-A;OPS\'?"9M;$84@F2#Q1XZ\:QR^:"Y9
M@&=E2-8_R&KD4_#C@?QQPM5.-?%<74."LGQ:<IRQ6%P>/P.;XO"Q?PJ$LIS;
M+8RJ).I%T'>I[2I5E4]55(8S$Y8^6]-X+ZS*-WK4E>/.];Z/HO=>]MD?U"1[
M@$!VAAOP"Z@2#<<,F "<CDC;P206. Q_!+_@I1_P1]^-W_!2#XFZ9K?BC]N?
M3?AU\%O!9$WPQ^#6G_LZ0>)QX3U34-+L].U_7-8\5+\9O"C^*]>UN>V*17]U
M86"Z5I,L.B6%LZ0RW-]^QWQY\$?$WXA?"SQ=X*^#_P 9M3_9^^(6NVME#X6^
M+ND>#?"WQ"U#P5=0WMM/=7,?@_QK9WOAC5X;RT@N-.=-6BD6,WK30>5<1P3)
M_!O!_P %/_\ @L'8_M:Q?LE>-OV\;_PAXEM?C^OP#\1>-)/@I^SM<:+H]^GC
M]/!-QXLM;.;X)VMS=:0&$NK6L"W-K+=:5<:6LCK)<7#-\+X1<,\4YEBLRS[@
MSB+(,BS7A/*:^95JF<4:F)Q&'R9T,73S#,,OH/)LXP]>6!H*5.N\1&$T\72=
M.4I2<X=>98K#T*,8XN+G2JM4U%/EN[Q23<7&7VKZ/HNA^L7PN_X-OOVB/@1>
M:UJ/P!_X*R_$[X-WGB>PLK+Q-??"[X2>._AO>>(+?2[JXN-,LM:_X0;]J#3W
MUB'2IKB^?3FU&2X.GG4=0%A'#]OO6F]5O?\ @B3_ ,%))1%9C_@NM^U1<6$T
M<R:@UQ>?M!6EQ$VSS(/($'[5;R2[W8K*KZGIYMX!'/FXW!!_0)\&?#/CSX;?
M"/PSX;^+OQBOOC7X[\)Z)=1^-?C3KGA;PGX&OO%MQ#=ZG>-XDU3PKX2M[#PK
MX>_LW3I8+.>PTJSMH6.F2RRPF625Y/YWO^"4/_!5_P")7[7/_!2K]KCX/>._
M'M]K'P9\?:1XK\;_ ++'A;4=/T.PL_ VD?"GQ=I^B7/AS3'TZQMM5OK_ ,8^
M!]7C\8ZQ+K.H:H[7?A_6)K:6*.XECG]C+N.?%?B3+^*>((8O),WH<%9?3QN-
MS*MP9P9BJN,RK!RA@<'5]OC^#OK=3GH4Z=2"Q#4Z>'C92C"$3%T,)0GA\,H3
MA]85Z<57KI1NN9IQ56UE>S;3N]^J7TY^P!_P1I^)W[">J_M0>.M-_;2N/B3\
M9/V@_AE_PA'A_P")6L?!ZX34? WBF.^N]9@\?Z]#XD^*_C2]^(5W;ZP]E<MH
M^IZGI$<D5J]L=2076;?Y-_:-_P"#>C]J/]K7QEI7C_\ :-_X*D/\4_%FB:!'
MX:T34M:_97LK$:3H:7ESJ3:9ING^'?C;H^E6]K)J%Y<WD[P6233W,TDTTCDI
M''^CG_!71OVN?AC^SUXU_:>_9F_;5OOV:-,_9Y^'7B;Q7XM^'T?P=^$/Q(TO
MXNZC'J6ESZ-:OK7Q!T/4[[PYK#,R^'=*M=,6.QO[O6;=+VSN)S R?(?[#'@;
M_@K9^UA^Q9HWQU\:_P#!3K6/A;XX^.__  C_ (\^&5LO[*_[//B>3X>?#_2[
MSQS:7$-Y /"/A6Q\2I\3+>^\->(XYXEMYM+T#P[HD^B3[M>U1#S9/Q7QG]4Q
M'B55\0."<HS;,,;EO#U2>:Y/%YQ&MEV"_LS!T,%.GP3..!H0RRM*C7H8">'H
M8NG/_:J=>NT:8C#X.,%@WAJU:-KQI4JE1S:B^:Z;J1;Y;.3NVTE+31G'?LN?
M\$2?VZOV'=1U"#]F7_@J#H_@WPGXPUK2=;^('AZ[_9BL[W2]=N]'!M(KIM+U
MWXB>*8K>^CT@O:+>6^J:,9P8%=&6TWWG].PN\<"-2-QQ^]0'!)(XP1WQ]ZO\
M\C]I3_@K-_P6#_93_:#^-_[.?B3]MV?Q9KGPC\:ZOX#N_$@^ O[--I:ZPNF+
M!/8^)=+LKOX.3W5A#J^GW=K?G3YKBY%LUP;=[B[$27$GZQ?L^?#?_@X\_:1^
M"WPR^.O@C_@I)\!-'\'_ !7\':5XU\-Z;XK\)> X/%5EI6L0^=:6^OV&A_L2
M:]I%KJ<31.MPFGZ[J%NT;NJ.L@22/Z#CS@3B_,J.7\7\:<?>&=-<0NKC,)F:
MHXS+*V:-X; >UJU/[/X*P_MO8X9X.T:L$J7M'.*C.K5;RPF*PT%/#83"9C+V
M%E4I.,&J+DY)>]-M^\XRTYFO=NM[O^M4WH!V^7EB"54.&9B,9'RJV.HR3C'4
M X.!+U6SN5%QGD2JPXZ@D*"",$$;>"".>"?X]?VO-&_X.._V-_@1XZ_:*^('
M_!03X/>,_A[\-]-T[5_%4?P]\'_"&;Q%96>I:UIWAZ.[M=+\:_LD>$+6\CLK
M_5K.26RBU9[F[C8J/L_E,DWZT:#X-_X*,?M;_L.?L/\ C[X1?MX6G[-/QDU[
MX+>&_&OQP\3WG[.7PE^*$?Q:\2>-O"WA[4K%;[3]5L-+T?X?1Z)=?VK-Y7@O
M0+:*ZEU![>YC,5K;+#^8YMP10RNAE.8+COA',,OS''/+)YCE^(SJKE66XF4%
M5B\VG_JU1Q%-QIRC*,<-!MTY1G*#5YG73Q52K.5*.%J0E!)OVS49ZVWY7R6W
MLUNK==_VD%V"ZIM493?DN0 OH<H"&[X].<U(DX9BK )QE?G#;E]> "#[<^Q/
M./\ -K\3_P#!;_\ X*[?#W7?&/@KQ!^V#>3:OX+\7>)="UNX@^"G[-5X#>^#
M]2?1=533+JX^!L;'2)-0T;5)5N)K"5D^T.KA($58_P"S[_@GA\,_^"AF@:?H
M/Q5_;._;=T;]HK0_B7\(/#NN:;\&M&_9^^&7PU7X:^-_%*^&/$@OXOB'X,TW
M1-5\7VNEZ6^K^'397.DZ58SM=2:DEK/-;Q?8/>XU\),\X R[ YGGW$/"U6.9
M<RRO!9=B,XK8W,W"WMO8QQ.287#Q^KTW+$5?:8FE>E2J>S<Y\M-QA,RP^.J5
MJ=",E+#J/.WL^9V6MWOY'W_\8?B?I_PK\-MKD]LNI:C>78L-)TKSA&MS>>0;
MB6ZN'"N\5I86L+3W+B.0J'A4%#*&'S#=_P##4NMZ=)XR;4+[1[%;=KZ#1K>>
MQTF[%K&O[U;?0GL9[P3I 9)"EW*Q5$+X)7GN/CXMBGQ#^#=]XD6.3PHVJW,.
MJ/=*%LTFCOM/G:6[9E2,VTT%G:QS&/:DT,;1D-;7$\<OLEI\6/A=XBO9= LO
M&6BS7U\)+$QQ7DUD9GNH9(MEM?7-O;6UW(V[Y564/YFT0)+,8XW_ "RF^:G&
M3UDW)-Z:VM9>JOV.X\4_9[^-GB/Q=J.H>&/%;?VQ>Q:.^K:3J2VT<%Y)#9A)
M+O3=5$">7+=%KF!+>1(49&@N-R2&<)'YAX1\4W'Q5\?:I8^.OB1X\\*3W]Q)
M:>%='\-:UJ.CZ7%?2W%REO:226I,*7D-G:Q1B$Q[KV]-TTC6LJ&%OLGP%\)?
M WP^N+Z\\-Z7/;7][%';W%Y>:A?7MP;>.9Y%@B:ZD"QQM,I9Y8X$FN0$6>:9
M(XUC\2^)UY\$_A7XKD\3Q^'X]6^(C7(U*QT2RO[Q;*TU26W#+JNIVD<QL-+0
MPR^<I%O<3L]TUY;:8\LPNC0'1_"_QMXETCQ_K7P>\;:F?$&HZ3;G4?#WB%E$
M-SJ&FM:QW44-^@:3=<&PG%T099&B8-"0PB$B_2PE^;:0!\I;.[TZ\;>W^17Y
MX? 1/$?CWXPS^/\ 5+@SMI,6HWVJZBL6+9KW5M-O=.TW24"+M6W2WU"Y)5$&
MQ--C *,1(/SY_P""I7_!=OX<_L.^(=6^!'P5\-6?QI_:7L+21?$7]I7J6WPR
M^$-S-;Q7%K;^.)]*E;6/%'B][)VU3_A!?#LVDI:V6R?Q!XFT 3:;::O[&3<-
M<0<2YQ2R/(,#5S#,JTIJMA:7+?!>RISJ5*M235EAZ4(>TQ-2;]RA&K.+YHI&
M5:M2P]*=:O+DIPY>:79SE&$?ODTEZH_H*?4HUD$(4/(^[8J2*257JQ4XE(]?
M*CE(]*ECN)WVAK5D8_>&\,%..?F";,;L#&X28.XH%YK^)[]FSPQ_P7*_X*^:
M-)\7-<_; UW]F3]FO6Y]6M=#\0^&K6^^'>D>((+:ZN]-O]/\!> /A?;>&/$O
MQ TG2=1T^^LKOQ+XZ^)>F6D^HVEWI]KJ[7EO)IEE]^S?\&]_CT6HU!O^"J'[
M8?\ PEMO9)86>JM>WJ:7%"C_ .C1)IH\<7]^J(Q^ZFK)/([*J2#<0?K,QX$R
M#AO%U,NXI\3N'L-F]!4OK.%R++\RSO 8.=2]Z.,Q="IAG2KTW>$X*55.4*BC
M[.5.4'S0Q=:JG.AA)5:3UC/F46UTLKO\NY_2_+?E&")"9"IQ*=[(L?.,*6C_
M 'QX8XC! VC>4#H3*EUO1GV+@-(%VR!PP0L#\RJ0&!7:R#)1\J>0:_AH_:[\
M)_\ !:?_ ((YZ?I_Q3TK]N'QC\:OV>;C7+?P_9^+-=O9?'VEZ=?S[YM'T;XA
M?"SXS'QD_A%O$ -U9V\G@#Q=KT%U+:[?^$HTZY:QM+;^@3]H+_@J?X?_ &'_
M -B/]G?XW_M/VT'B#]H/XO\ PI\"ZGIWP:\ +8Z'>>,?B#J_@K3_ !)XFN(H
M-9GO6\&> -"NIH[;5M>NY=0EL;B]@T+3[/5-;N]/A;DSCP[S/#KA[&<-Y]E'
M&> XKQL\MR=9+2Q5#&/%9;_M69*M@,:YXFA-8>I&BXU:TH+V?MZ?+"<93NGC
M8_[1]9HO#+"\KJRD[IJ<5-6=WI:25]V]+7V_8Y=05AC:@<XP@G1V*DX\P+&K
MOY?7#,BC(YP,D2-=2!E"V[NI!+,N\[<=/E$19@W.,=2" #7\.GP5_:__ ."U
M'_!9CXG^(/#7P"^+>B_LK_!7P[);P^-=>^'UK-X)\%^"Q>1'5],TN\^(4.EZ
MW\7/%_C?5=.AB2TT'PGXDTZPO+*[COKN/1M%_M74HOT:A_X("_&S5=.L=4\9
M_P#!6;]KG6?B&FFH\&N:9-K\&B0:JZ0/(ZV.N_$O4O$%U9F?$C6S^(-/O;J.
M%!/J&G;%!]7-/#; <+8I97QKXAY%P_G5-?[5DV RS,.,,TRVZDD\W_L7V&%H
MN4DE%492:OSSCR+WLH8^IB&GA,&Z]/WKSY^6W*FWHW?2W:UO-Z?TV-J*)&TC
M1.I4_<=95<_,0V8S#YJX4!P6C 8,-I*D,;QDP"0,].,X[@>A]?T/..:_@W_:
MOUK_ (+0_P#!&3QCX9U.\_:_\8_&SX$>)/$!TGPCXP\417GQ&^'FN7GV9M8O
MO"7C;P;\3?\ A*-0\ :]<VHN+JVTSPUXPL#KEA;:YK>A^)9+K3K[3C^^'_!)
M3_@M#X+_ ."A+7/PC^)>BZ9\*_VG="TJXUEO"]G>K)X/^)WA[3[>![[Q'\-Y
M[\Q:O%J.EAI9O%/@S5TDU33HUN=7T.[UOPW9WU_IN/$'A5Q%D_#5/C+)\SR;
MC#A24YP>;92L1AJ^':E%1699=B;5\!*?-RTU+G3G&K&5E!3"CCZ,ZLJ%63HU
ME9>S=FTW?9ZW^?9^A^[*/OSQC&,<YSG/;MT[T^H(1RW.<A.V.FX?7M4]?FL)
M<\(SM;F5[=O+Y;'H62T4N=;J6FM]>B2TVV"BBBJ **** "BBB@ HHHH YKQ'
MH6G^)_#^N^&-5C,NE^(M&U#P]J<( _>Z?K5I+IM[&"<K\]M<RI^/':O\C#XA
M^"]3^&_Q$^(?P[U:W^R:E\/?'OC3X?ZA:L%!MM1\$^)=2\-7]K)M9@9K6ZTZ
M2VF=6:&26-C$[H-U?Z\,X)BE;( D2,G)&$ ^8OR""R!=R\?>48YZ?YB?_!8#
MX8/\)?\ @IG^V3X<\AH++Q#\8=5^*VGNR*GVE/C)I^F_$[49T*YW1+KOBC5H
M$=F8.8FDVQ-(T*?T]]$_,XX3B;BS*[)PQ^2TLU]FWK4Q>"S*A#$0BEO[/VO*
MW?EE%7C=79\]Q*E*A0DVVHSO=)OX5S1[N_/%6\W>_?XUT'Q)\5?B7X5^'_[+
MWA:2?7=,U#XO77B3X?>#H8UA-W\6/BCIWA?X90W#7LK20%+VUL=+L)!.EO%I
MEJU]J:2?)=2I_JK_ +/'P1\-_LY?!#X2? KPB3)X<^$OP^\*^!=-N&BCMVOV
M\/:2EA>ZU-#$VU+W7;XWFJZ@O,?VF\)C^Z=O\ G_  ;Z?LZ1_'G_ (*/^"O$
MFJV37?A7]G3P1XI^.6JM)$QM$\2:;>:/X4^']K)-AHX[^7Q+XEBU^P\Y7,NG
M^$?$<:QJ4\Z+_1LQSGC\N?S]:Y/I/YQA*W%&!X4RR%/#TLJH5\XQSC=NIC.(
M8X64XRLN7FIPR^][\UZCOI9EY!&;H5,1433K>SBD[:JCSI;><]M#/O(C(T)[
MJDBKE0P:1MC+&P+IN1R@WHS+&X W.K*AK_+A_P""G_[/TG[,/[?_ .U+\'X;
M-K71+'XEWWC7P:%,LT4_@CXIVVG?$/PP\$\L<9N'LK7Q:FAZB8T$,.LZ7JEK
M$!':$#_4CNW9-FU=QP[#G&TJT8ST/.&)SD8Q^-?Q5?\ !TS^S^VE?%+]FK]I
M[3K#R[7QUX6U_P"!?BN\MXRK2:_X0O9/&W@N.XN/DA^VZAHVL^*H]/5R7FBT
M":(R+'$GE^']&KB5Y1XD?V/*?LZ7%&58W)[2ORU<QRBE#.<KHN6T'6KN48U9
MM44Y-2DFFUMG]"-7 >U>L\-K!6;T;=_*UVMS^7/2?B/XQ\/^!?'/PWTW6IK?
MP3\1=4\$ZYXOT,KYL.JZK\/'UF7PC>S32 3B32IO$&I.5 ,1>>YG0F2]N-O^
ME5_P1B^$)^"__!-#]DSP]<6JVNJ>+OAAIOQ@UI%P&%_\9[J]^)EM;R ,RI)I
MVA^)M'THQ9#Q"Q6.55F611_FH_#KP7>?$OXA> ?AUIZ/)?\ C[QKX4\%VJQ(
MTDGG^*=>L-$1HT0J[LGVTOY8*;PNTN@)8?ZY/@WPYIO@[PUH/A'1[>&STGPO
MH.A^'=+L[:+R+:STW0]-@TJQM;:$ *EM;VMG%# !@+&BH% 0%OTWZ4N:4</@
MN%>'\)!4ZN:9CC.*<UKK26.AA<+/*,EK36DE[3!U)5>2:]I2<8PJ1IRBD</#
MD6X8BI;W)<JB[[^]?;=?<O4ZBO\ -H_X+C^"-5_9]_X*L_''Q3I-K/;S^(-4
M^&G[1'AF6:2$M>7NJ:!I6H3R6X60GR5\9^%]9TR,N5WSZ=<"/>BAV_TEZ_B#
M_P"#J+X5?V9\??V6_CJL#RCQG\&O%GPGUB=0R6\<GPM\:W?C70XC,L@Q+-'\
M5?$[["J%(K8$/<"0K%^9?1RS'ZOXE4,HG44*/$N1Y[DU3FTC*4\#4JTX\UK1
MFZ=3'.%Y14G'D5YSIJ7HYQ3YL&ZBWHU(37HY)2=NMDMKH_=7_@K'^V GPH_X
M)9^-?B?X%U%9/&O[3GP\\'?"WX0SZ:\AN;K6_P!HWP^MBVK>'VA*RF_T_P )
MZMXD\0Z-*1Y<.IVNFW,Z^5%MK^)KP5%\1_\ @DG_ ,%)?A^?B?;V]KKO[.7Q
M$^'6M^/QHPE-E?\ PS\?^"_#^M^(1;QAV>[6Z^&?CS4D-O*PN[#Q#9RV#11S
MV4D"?M'^R!\0U_X*8?%[_@B[^RZDL6M?"_\ 8$_9WTCXT_M"6EL[2Z3=?$;X
M-ZGI7PS^%FD>)+"Z2ZAGO%M_ASX#U"W7SKA;G2_B;XFL[MV6X2>1_P#P='?L
MX-I/Q*_9U_:NTO3$^Q?$/P[K7P*\>:DEJQAG\2^$AJ'C#P,]W*(UMY+G4_#T
M_BJ-$E6:6YT/POJ(@WPZ9%#)^A>&4LNX2SQ^%&;8>4\)X@KBO'9Q0JITZE+%
M8FOF_#W",9J;YZ57'<)X/B"G&4XQ]G#/*,L0J7/353AQDGB</+,XWD\#"FL,
M[_&U2@ZKLTFFJEXO;6+=VM3]7?\ @XD^(<\?_!/K3_@SX+O89_$_[5GQY^"W
MPK\,BQ=[E=1L8/$>G?$@7EC)9EA>6%SJOA#PU9SK:RLU[8ZK((1+ )WC_:SX
M)_#O1?@[\'_A?\'O#=H;'P]\)_AG\/OAMH5H WE6NC>!?#-CX4TRSCD9W+K;
MVFC1! 2"(6A<C]X"?XSOV6_VAV_X*/?'/_@A1^SIJ5])J^I_LPZ+\4/B1\>(
M6$^H+87?P+CU.P^%TNM[HX EQXFT/X8^%8II!-??9+7XBZ8T\TES>RP'^WJU
MWD2H[*6582Q"%6#G<VTY9B$$;1>7$Q=H1E&FFX8?A/'N6XKA+(>&N!L35E+&
MX7,^)N(,RER2A]8JXK,ZO#F43V5E7R3AZGBUS/FIJI&%;EG.G&7K8><<2ZV*
MC[T)Q2I2=TW%1;;L]59R:U2=T?YB_P#P6./_ !M"_;;SG_DL$8Z]O^$#\$C'
MY<5_>K_P2GOK*;_@F_\ L96D=W9RW2? 'P,)+1KB!R!'"#+'/#O:1, ;)E=0
M4S@[217\%7_!8UMO_!43]MLXSCXP1M^7@/P6V/QVX_&OZ*OV%/\ @@3^PW\>
M_P!CS]G_ ..WQ%UKX^W7C3XI?"OPWXTU^+2/BFNB>']/UG5[<B[CT;2K300M
MIIBF-'2VNKB]F(0QS7,T4CQ'^A/%?!9'B_"/P?CGV;X[*:<*.6U<%+!Y+/.5
MB,7')9\D*JIYEE[PO)%WA-^UC/GFVZ?LU&KX66RKQS;,/8TU-2:]I><8-+VE
M5QMS6O=IZ+;<_93]H;]JSX">(?VK_A%_P34^)OPPM/B];?M4_#'QOXC\1C4K
MO0-9\"Z-X<\+?VC<6^B^,?#-Z+B?47\0S^&[N>Q$ MY[=[6"9CM7?'^B?A/P
M[HG@_P .:!X2\,:39:!X=\-:;;:#H&A:?#';6&CZ+I*+9:9I=C;Q9CAM+"R@
MAM+>)"RQPPHH=\;V_EH^$?\ P2<NOV#_ /@LA^RCXM^ 'ASXV^._V;O$/PQ^
M*>J^+?'OC'1KCQIIGPK\7S^'O%VC1>&_$_C_ $K0[2ST>'4X;CP[_P ([/XE
M*7][-<WT-M<7D5C(8_ZK86*1Q.%#8+KDE<C#-N!V KORK!^<[LY .<?RWQCE
M_#^4?ZNT>'\VQF:Y;CN':>:X[&.C'+ZE#,XU,=&OA:^7_6\96PDJ:P5:-.-2
MM+ZQ2A3Q*:IXNC&7T>$56?UB52*C-S2M>+O9+EL]$U97O?NMU9?Y'7[2O_)9
M?VCQZ_%WXWCZLWCKQ6J_J0,]J_UD?#>IVNC?#7PUK&HRR16&E^ ]'U#4)E#N
MT-I8^'(+ZYFVH&D=Q%;LBB-6=C(5569@#_DW?M,?)\9?VCCUV_&'XVCZX\?>
M*??_ #[U_JC>/HYY/V;=L'F8;P)X/^T^5N#_ -GI%H4FI\KR$_LY;KS#TV;@
MW!-?TG])V47@/"]7=U@,?1>C_B4\FX?<H[;*VC^%V5F]#Q<G_C9E_BHW_ ^=
MK5/$?[3OC/7TN=7_ +%TG0])N[S0-.:$26=E+<2Q6.FPS1?/)OO26N-4OHQ]
MHCCF:UB"QH,5_%_@3XFZSIF@>$G^#]M;:QHUPMHOB[0(U%IJ]M&#$DU_<6ZP
M6'DW!?[6;N[*70:!8KB"V$CLU7]F/Q+;Z%\0I;&_D$:>*M$O-*MY9"D4*ZM%
M<6M[90LY)027H26"U1BN^82 -E=K?I!+$K)APLI96$;%4D)RC!EBW9$;%<J,
M[@<D8.:_D^4N5KM\]/\ ,]V'7Y'P_P#%'XX:OX4TO2OAUH6II-XKTO0=(TKQ
M=XK,;>9'K0TNQ@U"ST2*14!U6=C/<W-W\\FGR7*10!KI+V*V^5=$&DZMXEL8
M_$^KW.F:??W[IK&M1QK=WT$4KNLEU-)-())&>96-Q<&W*M,6D.0=S?2C6VC_
M  D^/'B?6_'NFO)H.N7^OZ]X<UZ>Q>]L[?4/$>IW&LH2K2I;">R$EU8@2-')
M BVLBN6G,46K\=[+PYXX^&VB_%OP]ID^DO)J\>F3S7>GQZ9>ZAHMS=WNBP_:
MK=U8S+)?VMB]K,4'_$NNTN ICAQ()JR[/K]^G]=@E%MMI%S]KKXHZ'^Q5^Q-
M^T'\9/!EE:VLOPE^$_BGQ3X66X1;N.]\;3V;:/X4NKZXG:,:A)>>([[2()A/
M(B7$3A'D6&0,/\U7]FCX9:M^U=^UY\$?A5XIU6ZU#4_VA/V@_".B_$;Q!?WK
M3:S<V7Q!\;6^I_$7Q))?WPD.J:W+HESXDU%WNA')JFMB:.1)X;F,-_H2_M]?
M#SQ1\</^"2/[27@O3H;R^\3ZC^SYK&LZ-! LCWVJW'P_O;+Q?I%LB>5-(TVI
MVOA*S@VA)&9K@@;F.X_Y[_[$_P 8-&^!'[87[+'QJUN40>&?AU^T!\*_%'BF
M<%4:V\')XSTJ/QI?Q).0K7D7AFZUNYL8&G"7%R+2TFET_P"TK,O]8?1SI4Z/
M _BGF662_P",C6'S/+Z,DK5*.'P^5XO$X:?).W^\8F'L81EHZDX*22U?SV=Q
MOC<M;5H>U7-)OE2NTI7;V]UVZ/L?ZJW@OPOX?\$>$O#/@OPGI%KH'ACPEH>G
M>%?#6A6$2PV.D:'X?M8M*TO3K)$ 46EI96D,-L3AI(421_WC,*[.L33YX+JQ
ML;RTNK>]M9K5)[6[M)$FM+VWN$$EO=6DT9:.>VFB99+:XC9X[F%DFB9HW4UJ
M^:>Z?JQ_]D%?R!2ERNK.IS^UK8C$5L1*::?UJ=:7MHOG<924?<M4U4VY-2;O
M;Z9Z1A>_PI::K9=5=?<?)O[:_P"R!\*_VY/@??\ P!^,UYXQL/ NK>(O#7B:
MZNO >KZ5HGB--3\*:K;ZKI*VU]K6@>)-.6WDND"7<<NF^8\1_<W-LP\U?\[?
M_@K;\=[WXX?MY_'B6VOIW^'WP;UU?V?OA1H\DK?9-&^'_P &K&W\"Q1Z<$!:
M(:_KVF^(?&LWFK$MS>Z[<V=W;6-JL-M%_IWW :9X<HJK&S.SD@MM&W<H#QX^
MZ"YP>L:J00Q(_P I']N?P5JOP_\ VS_VLO!&MVEW9:CH/[0GQ:M98;F/S9&A
MOO%^J:MI\D<D4:))%>:1J-C?V$TBP)>VMS!.I(E61OZL^BG4>*XKXACB<7R4
M<HR657*L)4JJG"=/-:L)<4\BE)1Y\RH97D^63]YN4:BG*+ITIRA\[Q!)+#TZ
M;TAB6XU)-.R44^5-VLENTF^[/]!?_@BC\#-#^!'_  3>_9LTK2]+2QU;XD>%
M/^%U^-KT>4+G6?%OQ(E74?[1OI(W+7,L/AB'PUH=I(ZDKIFC6:2.7C1%_5KC
MC/4HP [G)))_ #DY_/-?G;_P2>^)&G?%7_@G1^QUXKTRYBO?+^!WA+PAJ#0.
MA^Q:I\/H9O!>IV-PB_*MS:7V@2VUQ&&+QNR/\Z2+(WZ'[FWQD)E &+'/W<\
M$8.>2PZC..1Z?S9Q7B,7C.+>*,5F7MZN+?%.>NM[2C5C55>MF;Q%!2A.$)QC
M*UW)Q4*25IN/*>[3?+0H/39*R?-JX^7-N[Z:VON?(?[>/[->E_M<?LG?'KX
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M\%>#CZ?\4KH?'M_QY5VU%)IMQ?/57+MRU:D4_P#$HR2G_P!O)VV!775_>_\
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MCC\3^+X[/4]2A*DOIFG&.:32M%=F;+_9HKR:XG9E#R37 $QD^SP>7]/A%4$
M<'.1]<ECGJ2Q)+$DDDY)S4-N) 7#A<!8QN  #.-XD( )PK$!U!/&\CJ#5FO,
MQ6(K9AB*N+K57*52K.4+KX$I.,4M=4HI*.BT6RNQI6278*0D#J0/J<4,0H).
M<#DX&3^0KX6_;D_:Z@_9?\+_  [TCPYI%AXF^,?QP\:V?PV^$7AK6'N(=';6
MM1U#1M,U#Q+X@-HDE^_A_P --KVE&]MK.%I;Z\U33;-I;."XEO;>1GW3D$D
M@D'!&1D' .#[X(./0@TM?%>M>+?C;\._BY\"_AOXFN?"_C?PA\9-=\5>']4^
M)%CHTW@W5- \1>#_ (2>-O'2>'(O"\6K:SI5ROBB7PD-5T'49KQ5L=-\.>*M
M.U:SO&;1]1O?L\3*1N"38Z',,H.?EXVE Q^^.0"HPV3\C[0"6BJZW,3*&7S&
M4@D%897X&>?D1@=RX= ,M(C(Z!E921;F)F*@2$@N"/+?C8YC))VX56=7",Q
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MTWPSH>G7-RWE7$=_JUQ )18-C\0_^"?K_"OPEXS_ ."@?[1'CZ7PW8#]FO\
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M\5WM_<6C^)O#_A72]%UR1]16>YNI;W4=/@@N=1BN)$=[FTNG:&YG:&=\/:Q
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:AGN;J\N;S[7=7+7"E% '>T444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G '@# 2(  A$! Q$!_\0
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M+7VE.:NDHW_IO\[/)R%V;MPCD.0,'((!&"#QSD\D9 -#SHH)WJNT%G=U(54
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M_P",/'_BW0_V8_#_ .U!Y_@#05UNWGU;^U_#GB&W\(:+HUU)9:[J/BV%H8;
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M@+Q/^U5\0_V6/V_?'*_M:_M)?'+2_@K\0OAE^U!\2?V>O@!#\%_@!J'P7O\
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M$=QK]@E>S^*OVRO@CX:_9\^/?[3NMOXEG^#G[-'B#XQZ7X[U^#PI+?RW]_\
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MY-MMMMMO=W=PLK[Z=_Z_ _?![2PD6#?#!(EI-'+;!K>%UM)XE*1O;AXF\B9
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MQX8L[KP5XNNX[[Q+X>^W:G VK7]E)8VMB#T^?Y[_ -6/?=<_;?\ V9O#-_\
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M,+3P GPJ\._$V\A^&=QX.C^'6N/<+X?\6W=]X]TKQ++H_AJK/Q<_X*=?M >
M/!O_  5?U.X^"_PA\)>+/^"?^G_L_:=\/=&\0?$'5?%&D^-_$7QP^'GASX@I
MJ_BW6(A\/8]1BTVP\;:)8:3\-?"'V/Q!XD\0Z/>^&= \6:IJOB;0FLOU!\>?
MLU^#_B?\7_AI\6?B#XE\>>*K7X.>(3XY^&'PNO\ 4=!MOA;X2^):>'=1\)VO
MQ*&C:9X;L/$GB'Q;I>A:[KUOH!\8>*M?T'PY=ZU?ZSH.AV&LFQO[+PGXD_\
M!-[]F[XLR?MD3>-+7Q[=3?MOZS\%?$7Q@:P\8R69T;Q)^SSX4\(^%?A1X@^'
M2QZ?M\)ZCX>B\%>'==D6Y36+'4M>MI;K4+.:RN9]-8#2S_K^M#\CK?\ X+ ?
MM8^(+_P#\ _">D_ !_CUXJ_:B_;J^$(^+'C#X0?%[PAX5?X4_L3_ ++^D_M&
MOXC\:?LH>(OBSH/QE^"OQ*^)^H>(-&^'7_"#_$#XBIJF@:*$^,%EH&K^%?%?
MA/3)/O/P;_P4C^(7Q)U#_@D=J'A_X+^&-%^'O_!2;P!;^//$7B76?%FIZGKW
MPYOH_P!FW6_CGJ7@+1/#5IH^F6][=6M_;6.DP^-M4UU[2>RCO_LOA2YDN$O[
M#LM7_P""1_[,FO:O+XYOM:^,:_&F^^-'QH^.^I_'VS\6^&K+XH:CXW_: ^"=
MG^SK\5+.:&+P0/AU9>$==^"^E:-X$L/#&E> =.L?#<>D6?B7PX=.\:&Z\1W/
MT='^P_\  2RN_P!BJ;0-$\0^%]/_ &!-)N]!_9T\.Z)XAN(]"T'0[KX3+\$X
MM%\0Q:C#J%YXFLK#P"!IMC+=7T=\EVHU&>ZN+AW9@';HFEY^B_6Y]B?Y_P _
MYY[4444""D/^>GJ.<GT_(]Z6D) ZXY]?\C^E '\I7C[QWI/[*_\ P4*_X+2_
M%?P%I&EZ[>?L<?L%?L^?M'?!GX=^,/%7C;4OAQX7^*&N>&?B]KGC/6H_"EGX
MIMHM.D\:-!HI\4W&F&QNKVWDM&^U1&2.6OT8^!7_  58\$KXR_:,T_\ :D^*
MOP ^'WP\^"'P?_8Y^(ECX[TO4M)TN75[O]I75_%'A#5YKVR\,?%[XX^'[WPY
MIWCS_A7?AC0]0\(^*-=L=/O/&FGVOB'6GNM0@2S^S?A9^TS^SS\?/BA\5_AU
MX \*>+_%6N^!?'OCCX%?&'QA/\$/%,'@"T\<_"V"V;Q%X"\1_$K4_#</AG5'
MTZWU33VTNQGU*]L]2AU6S.EB7SBJ_12?##X6JA5/A[X%A'V.'3SCP5X?C"V-
MO=VFHV]@P;2@OV6UO["QOH+1AY4%Y:6=R(Q-#;L@-OI:UOO/A+QY\1O%UG\?
M_P!MG6](EU37OB7^SY^QWX3\9_LT_#7^T-5;0=:M?&N@?%_7-9\;6'A&UU*V
MTOQCJWC/XE_#_1?AY>ZO?VM_=>&['P3IFBZ!<>'AXO\ $+^)OC_]D_\ :6\
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MA^,?AWXC?\(#\"_#_B*>ZT71-%\$:]J/BCQ_JUYK3^&[[3_A_P"'&\2^)?L
M_L[_ +2G[/5[^SY\/-?_ .%D:%X(^%?[.OQ,^'W[2EUXW^)5MXV^'_QA^.,?
MC7X;GX1_$'X">&O^$I\2'PCH4>D:7\:?$NOZA;^&?A3J6M:9\1?!MK\3M(\9
M_$BTU&7P1^P[1QL<LB,<@Y95)RH(4Y(Z@,0#U ) ZFE**>2JDXXR!QSN/;/)
MP3SR0#UH =_G\J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B ,4# 2(  A$! Q$!_\0
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M[PW*&T_PYJFL"W_XF%Y8*LDQGN-HC$@"4?VQ/V)1^TMJW@WXC_#_ .+/C#X
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$'*?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
